WO2024087806A1 - 非天然糖及其合成方法和应用 - Google Patents

非天然糖及其合成方法和应用 Download PDF

Info

Publication number
WO2024087806A1
WO2024087806A1 PCT/CN2023/112917 CN2023112917W WO2024087806A1 WO 2024087806 A1 WO2024087806 A1 WO 2024087806A1 CN 2023112917 W CN2023112917 W CN 2023112917W WO 2024087806 A1 WO2024087806 A1 WO 2024087806A1
Authority
WO
WIPO (PCT)
Prior art keywords
natural
sugar
trimethylsilane
groups
protected
Prior art date
Application number
PCT/CN2023/112917
Other languages
English (en)
French (fr)
Inventor
陈兴
成波
Original Assignee
北京大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 北京大学 filed Critical 北京大学
Publication of WO2024087806A1 publication Critical patent/WO2024087806A1/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C07H13/06Fatty acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • C07H5/06Aminosugars
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the present invention relates to the technical field of organic chemical synthesis, and in particular to a non-natural sugar and a synthesis method and application thereof.
  • Glycosylation modification has important functions, and it is of great significance to observe glycosylation modification.
  • metabolic labeling with non-natural sugars with chemical reporters has been widely used for sugar imaging and glycoproteome analysis.
  • chemoenzymatic methods add non-natural sugars with chemical reporters to sugar chains under the action of glycosyltransferases for further study.
  • Non-natural sugars are necessary for metabolic labeling and chemoenzymatic labeling. They are divided into three categories:
  • Non-natural sugars without protecting groups can be used for metabolic labeling but require high concentrations, and are also synthetic substrates for non-natural nucleoside sugars used in chemoenzymatic methods;
  • Fully acetylated sugars developed to overcome the poor cell permeability of non-natural sugars without protective groups, significantly reducing the concentration required for metabolic labeling.
  • the existing fully acetylated non-natural sugar probes have been commercialized and are sold by companies such as Sigma-Aldrich and Click Chemical Tools.
  • non-natural sugars with partial hydroxyl acylation came into being. While they can easily pass through the cell membrane to achieve efficient sugar metabolism labeling, they will not introduce the S side reaction.
  • Method 1 is to first synthesize a sugar derivative with a halogen at the N-acyl position, and then introduce azide into the N-acyl position of the sugar by replacing the halogen with azide;
  • Method 2 is to first synthesize azidoacetic acid and then Azidoacetic acid and amino sugars are coupled to obtain non-natural sugars containing azide at the N-acyl position.
  • Non-natural sugars containing other orthogonal groups (such as alkynyl) and unprotected hydroxyl groups are synthesized using the strategy of directly coupling amino sugars and small molecules containing orthogonal groups in the above method 2.
  • Unprotected non-natural sugars are very polar, and when chromatographic purification is performed using a silica gel column, impurities and products often co-elute. Therefore, repeated column chromatography purification is required to obtain sufficiently pure unprotected sugars. There are a few reports that unprotected sugars are purified using a P-2 gel column, but the operation is time-consuming, the gel column is expensive, and can only be used to purify a small amount of product.
  • 1,3-bis-acylated non-natural sugars are divided into two categories: 1,3-bis-acylated non-natural sugars and 1,6-bis-acylated non-natural sugars.
  • 1,3-bis-acylated non-natural sugars There are multiple reported examples of 1,3-bis-acylated non-natural sugars, and only 1,6-Pr 2 GalNAz is a 1,6-bis-acylated non-natural sugar.
  • the synthesis of 1,3-bis-acylated non-natural sugars is to first synthesize a non-natural sugar without a protecting group and use it as a starting material, then protect the 4th and 6th positions of the sugar with propylidene, acylate the hydroxyl groups at the 1st and 3rd positions, and finally remove the propylidene protection to obtain the 1,3-bis-acylated non-natural sugar.
  • this synthetic route when synthesizing a non-natural sugar raw material without a protecting group, the above-mentioned problems are faced, and when synthesizing a 1,3-bis-acylated non-natural sugar from a non-natural sugar without a protecting group, the overall yield is low.
  • azidoacetic acid is required as a raw material, and the synthesis of azidoacetic acid faces the above-mentioned problems.
  • the main purpose of the present invention is to provide a non-natural sugar and a synthesis method and application thereof, so as to solve the technical problems of the prior art in the synthesis and application of non-natural sugars.
  • a method for synthesizing non-natural sugars comprising: protecting the hydroxyl groups of amino sugars with trimethylsilane at room temperature to selectively expose the amino groups on the sugars, and coupling and converting the amino groups at room temperature to obtain non-natural sugars with orthogonal groups protected with trimethylsilane.
  • the trimethylsilane protecting group is removed from the fully trimethylsilane-protected non-natural sugar with orthogonal groups to obtain a non-natural sugar without a protecting group.
  • non-natural sugar without a protecting group is any one of GalNAz, GlcNAz, ManNAz, GalNAl, GlcNAl and ManNAl;
  • the trimethylsilyl protecting group is removed by using a hydrogen ion exchange resin, and the final product is precipitated from the solvent;
  • hydroxyl groups at positions 1 and 6 of the non-natural sugar with orthogonal groups protected by trimethylsilyl trimethylsilane are protected by hydrophobic groups to obtain a partially acylated non-natural sugar.
  • hydrophobic group is any one of acetyl, propionyl, butyryl and valeryl.
  • the orthogonal group of the non-natural sugar with orthogonal groups protected by all trimethylsilane is any one of azide, terminal alkyne, terminal olefin, cyclopropene, trans-cyclooctene and cyclooctyne.
  • a partially acylated non-natural sugar for metabolic labeling which is any one of 1,6-Ac 2 GalNAz, 1,6-Pr 2 GalNAz, 1,6-Bu 2 GalNAz, 1,6-Ac 2 GlcNAz, 1,6-Pr 2 GlcNAz, 1,6-Bu 2 GlcNAz, 1,6-Ac 2 ManNAz, 1,6-Pr 2 ManNAz, 1,6-Bu 2 ManNAz, 1,6-Pr 2 ManNAz and 1,6-Pr 2 ManNProc.
  • the partially acylated non-natural sugar for metabolic labeling is prepared by the above method.
  • the invention also discloses a sugar metabolism labeling kit, which comprises the above-mentioned partially acylated non-natural sugar.
  • the present invention also discloses the use of the partially acylated non-natural sugar in a sugar metabolism labeling kit to label sugar metabolism of any one of HeLa cells, 3T3 cells, CHO cells and MCF-7 cells.
  • the present invention has at least the following beneficial effects:
  • the non-natural sugars and their synthesis methods and applications provided by the present invention provide a method for efficiently synthesizing non-natural sugars without protecting groups in large quantities (10 grams).
  • the reaction conditions are mild and the operation is simple, and no chromatographic column purification is required.
  • These non-natural sugars include non-natural sugars without protecting groups and non-natural sugars with partially protected hydroxyls.
  • the non-natural sugars with partially protected hydroxyls disclosed in the present invention take into account the advantages of existing non-natural sugars, ensuring that the non-natural sugars can be efficiently utilized by cells, and effectively avoiding S side reactions with cysteine in proteins during the metabolism of non-natural sugars. At the same time, efficient metabolic labeling is achieved.
  • the use concentration of 1,6-diacylated non-natural sugars is one order of magnitude lower than that of non-natural sugars without protecting groups.
  • FIG1 shows a reaction result diagram of incubating 1,6-bisacyl sugar with HeLa cell protein lysates or single protein according to an embodiment of the present invention
  • FIG2 shows a result of efficient metabolic labeling of 1,6-bis-acylated sugars in HeLa cells according to an embodiment of the present invention
  • FIG3 shows a diagram of efficient metabolic labeling of 1,6-bis-acylated sugars in different cells according to an embodiment of the present invention
  • FIG. 4 shows a diagram of efficient metabolic labeling of mice in vivo using 1,6-Pr 2 GalNAz and 1,6-Pr 2 ManNAz according to an embodiment of the present invention.
  • the embodiment of the present invention discloses a method for synthesizing non-natural sugars, comprising: protecting the hydroxyl groups of amino sugars with trimethylsilane at room temperature, selectively exposing the amino groups on the sugars, coupling and converting the amino groups at room temperature, and obtaining non-natural sugars with orthogonal groups protected by trimethylsilane.
  • the orthogonal groups of the non-natural sugars with orthogonal groups protected by trimethylsilane are any one of azide, terminal alkyne, terminal olefin, cyclopropene, trans-cyclooctene, and cyclooctyne.
  • the trimethylsilane protecting group of the non-natural sugars with orthogonal groups protected by trimethylsilane is removed to obtain non-natural sugars without protecting groups.
  • the non-natural sugars without protecting groups can be any one of GalNAz, GlcNAz, ManNAz, GalNAl, GlcNAl, and ManNAl; in the synthesis process of GalNAz, GlcNAz, and ManNAz, the trimethylsilane protecting group is removed by hydrogen ion exchange resin, and the final product is precipitated from the solvent; in the synthesis process of ManNAl, the trimethylsilane protecting group is removed by silica gel column chromatography.
  • the hydroxyl groups at positions 1 and 6 of the above-mentioned all-trimethylsilyltrimethylsilane-protected non-natural sugar with orthogonal groups are protected by hydrophobic groups to obtain partially acylated non-natural sugars.
  • the hydrophobic group can be any one of acetyl, propionyl, butyryl and valeryl.
  • pyridine is used as a solvent, four equivalents of carboxylic acid and a large excess of the corresponding anhydride are added, and the trimethylsilane protecting groups at positions 1 and 6 of the fully trimethylsilane-protected non-natural sugars are exchanged for corresponding ester bonds.
  • the trimethylsilane protecting groups at positions 3 and 4 are removed using a hydrogen ion exchange resin to obtain 1,6-bis-acylated non-natural sugars; for mannose-type fully trimethylsilane-protected non-natural sugars with orthogonal groups, two equivalents of ammonium acetate are added in a mixed solvent of dichloromethane and methanol to selectively and simultaneously remove the trimethylsilane protecting groups at positions 1 and 6, and ester bonds are protected at positions 1 and 6 in pyridine, and then the trimethylsilane protecting groups at positions 3 and 4 of the sugar are removed to obtain 1,6-bis-acylated mannose-type non-natural sugar derivatives (which also belong to non-natural sugars).
  • Some embodiments of the present invention also disclose a partially acylated non-natural sugar for metabolic labeling, which is a hexose and a pyranose structure, and has acyl modifications on the hydroxyl groups at the first and sixth positions of the sugar.
  • the non-natural sugar is a non-natural sugar whose 1-hydroxyl and 6-hydroxyl are protected by hydrophobic groups, wherein the non-natural sugar is generally a derivative of a hexose with partially protected hydroxyl groups.
  • the hydrophobic group is an acetyl group, a propionyl group, a butyryl group or a valeryl group.
  • the partially acylated non-natural sugar for metabolic labeling is prepared by the above-mentioned synthesis method, that is, the hydroxyl groups of the sugar are fully protected by trimethylsilane (TMS) to selectively expose the amino groups on the sugar; the amino groups are coupled and chemically converted to obtain a fully TMS-protected non-natural sugar with orthogonal groups.
  • TMS trimethylsilane
  • non-natural sugars without protecting groups and partially acylated non-natural sugars can be efficiently synthesized.
  • Non-natural sugars without protecting groups are GalNAz, GlcNAz, ManNAz, ManNAl and ManNProc.
  • the partially acylated non-natural sugar is any one of 1,6-Ac 2 GalNAz, 1,6-Pr 2 GalNAz, 1,6-Bu 2 GalNAz, 1,6-Ac 2 GlcNAz, 1,6-Pr 2 GlcNAz, 1,6-Bu 2 GlcNAz, 1,6-Ac 2 ManNAz, 1,6-Pr 2 ManNAz, 1,6-Bu 2 ManNAz, 1,6-Pr 2 ManNAz, 1,6-Pr 2 ManNAz, and 1,6-Pr 2 ManNProc.
  • Some embodiments of the present invention also disclose a sugar metabolism labeling kit, including the above-mentioned partially acylated non-natural sugar.
  • the hydroxyl groups at positions 1 and 6 of the partially acylated non-natural sugar are protected.
  • the partially acylated non-natural sugar is a hexose analog protected at positions 1 and 6.
  • the partially acylated non-natural sugar is a non-natural sugar whose hydroxyl groups at positions 1 and 6 are protected by hydrophobic groups. It can achieve sugar metabolism labeling of any one of HeLa cells, 3T3 cells, CHO cells and MCF-7 cells.
  • the above embodiments of the present invention are based on the strategy of full TMS (trimethylsilane) protection, and develop a method for large-scale and efficient synthesis of non-natural sugars without protecting groups (target compound category 1) and high-efficiency synthesis of 1,6-bis-acylated non-natural sugars (target compound category 2).
  • the embodiments of the present invention start from amino sugars containing six carbon atoms, and perform TMS protection on all hydroxyl groups on the sugars, selectively expose the amino groups on the sugars, and further couple and transform to obtain fully TMS-protected non-natural sugars with orthogonal groups.
  • the full TMS protection method selectively exposes the amino groups, on the one hand, it can avoid the hydroxyl groups on the sugars from participating in or interfering with the subsequent coupling reaction when TMS protection is not performed; on the other hand, during the coupling, the reaction can be carried out in a solvent that does not contain hydroxyl groups.
  • the fully TMS-protected non-natural sugar obtained by the above method does not require column chromatography purification, and the TMS protecting group can be removed by hydrogen ion exchange resin to obtain a non-natural sugar without a protecting group (target compound category 1, GalNAz, GlcNAz, ManNAz and ManNAl have been successfully synthesized in large quantities).
  • target compound category 1 GalNAz, GlcNAz, ManNAz and ManNAl have been successfully synthesized in large quantities.
  • the fully TMS-protected non-natural sugar obtained by the above method can be purified by a simple silica gel column and then undergo two simple reactions to obtain 1,6-diacylated non-natural sugar.
  • Two technical routes have been developed for different sugars:
  • pyridine was used as solvent, four equivalents of carboxylic acid and a large excess of the corresponding anhydride were added, and the TMS at positions 1 and 6 of the fully TMS-protected non-natural sugars were exchanged into corresponding ester bonds. After the TMS protecting groups at positions 3 and 4 were removed using hydrogen ion exchange resin, 1,6-diacylated non-natural sugars were obtained.
  • 1,6-bis-acylated non-natural sugars including 1,6-Ac 2 GalNAz, 1,6-Pr 2 GalNAz, 1,6-Bu 2 GalNAz, 1,6-Ac 2 GlcNAz, 1,6-Pr 2 GlcNAz, 1,6-Bu 2 GlcNAz, 1,6-Ac 2 ManNAz, 1,6-Pr 2 ManNAz, 1,6-Bu 2 ManNAz, 1,6-Pr 2 ManNAz, and 1,6-Pr 2 ManNAl, can be synthesized with high efficiency.
  • the advantages of the synthesis method disclosed in the embodiments of the present invention are: the fully TMS-protected sugar derivatives have a smaller polarity and have good solubility in many low-polarity solvents (such as dimethylformamide, dichloromethane, ethyl acetate, petroleum ether, acetonitrile, etc.), and can be easily subjected to various chemical transformations (such as replacing halogens with azides) to obtain various fully TMS-protected non-natural sugars containing orthogonal groups.
  • low-polarity solvents such as dimethylformamide, dichloromethane, ethyl acetate, petroleum ether, acetonitrile, etc.
  • chemical transformations such as replacing halogens with azides
  • the synthesized 1,6-bis-acylated sugar can easily pass through the cell membrane and enter the cell. In sugar metabolism labeling experiments, it can effectively avoid S side reactions and maintain a high metabolic efficiency.
  • the main purpose of the present invention is to provide a method for synthesizing non-natural sugars in large quantities and with high efficiency, and to carry out its application research.
  • the newly reported 1,6-diacylated non-natural sugars in the present invention can improve the efficiency of sugar metabolism labeling without introducing S side reactions.
  • Non-natural sugars Chemical modification of natural monosaccharides to attach bio-orthogonal groups such as azide and alkyne.
  • Non-natural sugars can be taken up by cells, integrated into sugar chains through natural sugar metabolic pathways, and then glycans can be labeled, imaged, or enriched through bio-orthogonal reactions.
  • Bioorthogonal reactions chemical reactions that can be carried out in living cells or tissues without interfering with the biochemical reactions of the organism itself. They are used to study biological macromolecules such as nucleic acids, proteins, sugars or lipids.
  • the present invention solves the reported non-natural
  • the present invention solves the problem of chemical synthesis of natural sugars and discloses a class of 1,6-bis-acylated non-natural sugars with novel structures.
  • This application studies and improves the existing method of synthesizing non-natural sugars, develops a strategy based on full TMS protection, and develops a method for synthesizing a large amount of non-natural sugars without protecting groups; at the same time, starting from the non-natural sugars with full TMS protection, 1,6-diacylated non-natural sugars can be efficiently synthesized. 1,6-diacylated non-natural sugars can easily pass through the cell membrane and enter the cell. In the sugar metabolism labeling experiment, S side reactions can be effectively avoided, and a high metabolic efficiency can be maintained.
  • the present application starts from amino sugars containing six carbon atoms, and all hydroxyl groups on the sugars are protected by TMS, selectively exposing the amino groups on the sugars. After coupling the amino groups with various small molecules, various fully TMS-protected acyl-substituted amino sugar derivatives are obtained.
  • the fully TMS-protected sugar derivatives have a relatively small polarity and have good solubility in many low-polarity solvents (such as dimethylformamide, dichloromethane, ethyl acetate, petroleum ether, acetonitrile, etc.), and can be subjected to various chemical transformations (such as replacing halogens with azide) to obtain various fully TMS-protected non-natural sugars (the fully TMS-protected non-natural sugars contain orthogonal groups such as azide or alkynyl).
  • the TMS protecting group is removed by hydrogen ion exchange resin, filtered, and after the filtrate is concentrated, ethanol is added, and the precipitated solid is a non-natural sugar without a protecting group.
  • the non-natural sugars with orthogonal groups fully TMS-protected are an important intermediate.
  • 1,6-diacylated non-natural sugars can be obtained through two simple steps.
  • pyridine is used as solvent, four equivalents of carboxylic acid and a large excess of the corresponding anhydride are added, and the TMS at positions 1 and 6 of the fully TMS-protected non-natural sugars are exchanged into corresponding ester bonds, and the TMS at positions 3 and 4 are removed.
  • a 1,6-bis-acylated non-natural sugar is obtained; for the mannose-type fully TMS-protected non-natural sugar, two equivalents of ammonium acetate are used in a mixed solvent of dichloromethane and methanol to selectively and simultaneously remove the TMS protecting groups at the 1st and 6th positions of the sugar, and the ester bonds at the 1st and 6th positions are protected in pyridine, and then the TMS protecting groups at the 3rd and 4th positions of the sugar are removed to obtain a 1,6-bis-acylated mannose-type non-natural sugar derivative.
  • 1,6-bis-acylated sugars did not undergo S side reactions with proteins; at the same time, 1,6-bis-acylated sugars all had high metabolic labeling efficiency.
  • different ester bond protecting groups have different degrees of improvement in metabolic labeling efficiency. For example, the efficiency improvement of acetyl group is not large compared with propionyl group, butyryl modification and propionyl modification can significantly improve the metabolic efficiency of non-natural sugars.
  • 1,6-bis-propionylated sugars can also be used for efficient metabolic labeling in living mice.
  • the orthogonal groups contained are not limited to azide and alkynyl groups, and non-natural sugars without protecting groups containing other orthogonal groups can be synthesized using this strategy.
  • Other orthogonal groups include but are not limited to terminal olefins, cyclopropenes, trans-cyclooctenes, and cyclooctynes. Therefore, the synthesis of these unprotected non-natural sugars is protected by this patent.
  • the applicable substrates are not limited to galactosamine derivatives, glucosamine derivatives and mannosamine derivatives, and other amino-containing sugars can be used as substrates for this type of synthesis. Therefore, the synthesis of these non-natural sugars without protecting groups is protected by this patent.
  • the acyl groups used are not limited to acetyl, propionyl and butyryl, and other acyl groups can also be introduced using the method of the present application. Therefore, other acylated partially acylated non-natural sugars are also protected by this patent.
  • a simple and efficient method is provided to synthesize non-natural sugars without protecting groups. Specifically, GalNAz, GlcNAz, ManNAz and ManNAl, and synthesize the above-mentioned partially acylated non-natural sugars.
  • a sugar metabolism labeling kit comprising any one of the above-mentioned partially acylated non-natural sugars.
  • the use of any of the above-mentioned partially acylated non-natural sugars or the above-mentioned kit in sugar metabolism labeling is provided.
  • the use of the partially acylated non-natural sugar metabolism labeling of the present application not only has a high metabolic efficiency, but also does not have a side reaction with cysteine in the protein.
  • the above-mentioned application includes sugar metabolism labeling of any of the following cells: HeLa cells, MCF-7 cells, CHO cells and 3T3 cells.
  • 1,6-Pr 2 GalNAz and 1,6-Pr 2 ManNAz are used to metabolically label living mice.
  • the 1,6-bis-acylated non-natural sugars of the present invention are a better choice, and when synthesizing 1,6-bis-acylated sugars in the present invention, it starts from fully TMS-protected sugars, and the synthesis is simpler and more efficient.
  • steps I, II, III, and IV are as follows:
  • GalN hydrochloride (compound 1a, 100 mmol, 21.5 g) was dispersed in 200 40.3 g of HMDS (250 mmol) was added in batches to 10 ml of anhydrous acetonitrile and reacted at room temperature for 3 hours. The mixture was filtered and the filtrate was concentrated in vacuo to obtain compound 1b as an oily product, which was used directly in the next step without purification.
  • the 1c obtained in the previous step was dissolved in 150 ml of DMF, and 6.8 g (100 mmol) of sodium azide was added and stirred at room temperature overnight.
  • the mixture was diluted with 200 ml of ethyl acetate, the organic phase was washed with water, and the aqueous phase was extracted once with 100 ml of ethyl acetate.
  • the organic phase was washed twice with saturated brine and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated in vacuo to obtain a yellow oil 1d, which was used directly in the next step without purification.
  • steps I and II are as follows:
  • a crude compound 3b was synthesized from 18.7 mmol of ManN hydrochloride (3a).
  • the crude compound 3b was dissolved in 50 ml of dichloromethane, cooled to 0°C in an ice-water bath, and 4b obtained in the first step was added dropwise to the above solution.
  • the reaction was stirred at room temperature for 2 hours. After the reaction was completed, the residue was concentrated in vacuo. 100 ml of n-hexane was added to the residue, stirred and filtered, and the filtrate was concentrated in vacuo to obtain a yellow oil 3f, which was used directly in the next step without purification.
  • the 3f obtained in the previous step was dissolved in 50 ml of methanol, and two grams of hydrogen ion exchange resin was added. The reaction was stirred at room temperature for 2 hours, and the reaction was complete. The filtrate was filtered and concentrated in vacuo to obtain a residue, which was purified by silica gel column to obtain 3.06 grams of compound 3g (ManNAl). The three-step yield was 64%. The product was a mixture of end isomers, ⁇ / ⁇ , 3/1.
  • Example 3 Synthesis of 1,6-Ac 2 GalNAz, 1,6-Pr 2 GalNAz, 1,6-Bu 2 GalNAz, 6-Ac 2 GlcNAz, 1,6-Pr 2 GlcNAz and 1,6-Bu 2 GlcNAz.
  • steps I and II are as follows:
  • Step I general method for synthesizing 1f, 1g, 1h, 2f, 2g and 2h: 0.5 mmol of 1d or 2d is dissolved in 1 ml of pyridine, and 0.75 ml of anhydride and 2.0 mmol of the corresponding carboxylic acid are added under nitrogen protection.
  • the reaction is carried out at room temperature for 20 hours, the reaction solution is diluted with ethyl acetate, and the organic phase is washed with 1 mol/L dilute hydrochloric acid, saturated sodium bicarbonate solution and saturated brine in sequence.
  • the organic phase is dried over anhydrous sodium sulfate, filtered after drying, and the filtrate is concentrated in vacuo.
  • the residue is purified by silica gel column to obtain the corresponding product.
  • 1d is an intermediate in the synthesis of 1e from 1a and can be purified by flash chromatography using a silica gel column with petroleum ether and ethyl acetate as eluents. Starting from 20 mmol of 1a, 4.1 g of 1d can be synthesized with a three-step yield of 37%. Product configuration.
  • Example 4 Synthesis of 1,6-Ac 2 ManNAz, 1,6-Pr 2 ManNAz, 1,6-Bu 2 ManNAz, 1,6-Pr 2 ManNAl and 1,6-Pr 2 ManNProc.
  • steps I and II are as follows:
  • 3d The synthesis and purification of 3d was similar to that of 1d. 4.1 g of 3d was synthesized from 20 mmol of 3a with a three-step yield of 37%. ⁇ isomer.
  • 3i was synthesized from 3f by referring to the synthesis of 3h in Example 4. The yield was 67%. The product was an end group isomer, ⁇ / ⁇ , 4/1.
  • 3j was synthesized using 3g as the raw material.
  • the synthesis method was similar to the synthesis of 3h in Example 4.
  • the yield is 63%.
  • the product is an end isomer, ⁇ / ⁇ , 1.0/0.11.
  • 3l was obtained by the synthesis route of 3k in Example 4, with 3h and propionic anhydride as raw materials. The two-step yield was 81%. ⁇ isomer.
  • 3m was prepared by the synthesis route of 3k in Example 4, with 3h and butyric anhydride as raw materials.
  • the two-step yield was 79%. ⁇ / ⁇ , 1.35/1.
  • 3n was synthesized from 3i in two steps, and the synthesis method was similar to that of 3l in Example 4. The total yield of the two steps was 83%. ⁇ / ⁇ , 1.0/0.33.
  • 3o. 3o was synthesized from 3j in two steps.
  • the synthesis method was similar to that of 3l in Example 4.
  • the total yield of the two steps was 79%. ⁇ / ⁇ , 1.0/0.15.
  • Example 5 In vitro reaction of 1,6-Ac 2 GalNAz, 1,6-Pr 2 GalNAz, 1,6-Bu 2 GalNAz, 6-Ac 2 GlcNAz, 1,6-Pr 2 GlcNAz, 1,6-Bu 2 GlcNAz, 1,6-Ac 2 ManNAz, 1,6-Pr 2 ManNAz, 1,6-Bu 2 ManNAz and proteins.
  • Example 6 Metabolic labeling effect of 1,6-Ac 2 GalNAz, 1,6-Pr 2 GalNAz, 1,6-Bu 2 GalNAz, 6-Ac 2 GlcNAz, 1,6-Pr 2 GlcNAz, 1,6-Bu 2 GlcNAz, 1,6-Ac 2 ManNAz, 1,6-Pr 2 ManNAz, and 1,6-Bu 2 ManNAz on living cells.
  • HeLa cells were metabolically labeled with the above-mentioned different compounds.
  • the specific operation steps are as follows:
  • Example 7 1,6-Pr 2 ManNAz, 1,6-Pr 2 ManNAl and 1,6-Pr 2 ManNProc are used for metabolic labeling of living cells.
  • Example 8 1,6-Pr 2 GalNAz and 1,6-Pr 2 ManNAz were used for metabolic labeling in mice.
  • mice were intraperitoneally injected with 1,6-Pr 2 GalNAz or 1,6-Pr 2 ManNAz (both at a concentration of 500 mg/kg) every day for 3 or 7 consecutive days.
  • the mice were euthanized on the 4th or 8th day, and different organs were selected for homogenization.
  • the azide-modified glycoproteins were click-labeled and separated by SDS-PAGE.
  • In-gel fluorescence analysis showed that glycoproteins from the heart, lungs, and spleen could be well labeled, indicating that 1,6-Pr 2 GalNAz and 1,6-Pr 2 ManNAz can be well used for in vivo metabolic labeling (Figure 4).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Saccharide Compounds (AREA)

Abstract

本发明公开了一种非天然糖及其合成方法和应用。室温下,将氨基糖的羟基进行全三甲基硅烷保护,选择性地暴露糖上的氨基,将氨基在室温下进行偶联、转化后,得到全三甲基硅烷保护的带有正交基团的非天然糖。将全三甲基硅烷保护的带有正交基团的非天然糖脱除三甲基硅烷保护基,得到不带保护基的非天然糖。本发明兼顾了现有非天然糖的优点,既保证了非天然糖可以高效地被细胞所利用,也有效避免了非天然糖代谢过程中与蛋白中半胱氨酸发生S副反应,同时实现高效代谢标记。在细胞试验中,1,6-双酰化的非天然糖的使用浓度比不带保护基的非天然糖低一个数量级。

Description

非天然糖及其合成方法和应用 技术领域
本发明涉及有机化学合成技术领域,具体涉及一种非天然糖及其合成方法和应用。
背景技术
糖基化修饰具有重要的功能,对糖基化修饰进行观测具有重要意义。在细胞中,使用带有化学报告的非天然糖的代谢标记已被广泛用于糖成像和糖蛋白组分析。在体外,化学酶法在糖基转移酶的作用下为糖链添加上带有化学报告的非天然糖用于进一步研究。
非天然糖是代谢标记和化学酶法标记所必须的。分为三大类:
a.不带保护基的非天然糖:可用于代谢标记但浓度要求高,同时是化学酶法使用的非天然核苷糖的合成底物;
b.全乙酰化糖:为克服不带保护基的非天然糖细胞通透性差而开发,显著降低代谢标记所需浓度。现阶段已有的全乙酰化保护的非天然糖探针已经商品化,在Sigma‐Aldrich、Click Chemical Tools等公司都有出售。
但在2018年人们首次发现,全乙酰化糖与蛋白质半胱氨酸的巯基发生非酶催化的S副反应,对成像、质谱鉴定等应用引入假阳性信号。
c.部分保护的非天然糖:在S副反应发现后,部分羟基酰化的非天然糖应运而生,在容易穿过细胞膜实现高效率的糖代谢标记的同时,不会引入S副反应。
现阶段,主要有两种方法用于制备N-酰基位含叠氮且羟基不被保护的非天然糖。方法一是先合成N-酰基位带有卤素的糖衍生物,然后通过叠氮取代卤素,将叠氮引入到糖的N-酰基位;方法二是先合成叠氮乙酸,后将 叠氮乙酸和氨基糖偶联得到N-酰基位含叠氮的非天然糖。含有其它正交基团(如炔基)且羟基不被保护的非天然糖,则是利用上述方法二中将氨基糖和含正交基团小分子直接偶联的策略进行合成。
但这两类合成方法都存在缺点,方法一中,叠氮钠是大过量的且反应需要加热,有爆炸的风险;方法二中,叠氮乙酸的合成以碘乙酸和过量的叠氮钠为原料,为提高叠氮乙酸产率,需要将含有过量叠氮钠的水溶液进行酸化并用有机溶剂萃取叠氮乙酸,该操作有爆炸的风险。而且,叠氮乙酸沸点低易挥发,需要小心操作且只能完成小量合成。不保护的非天然糖极性很大,采用硅胶柱进行色谱纯化时,杂质和产物往往共洗脱。因此,需要反复的柱色谱纯化才能拿到足够纯的不保护的糖。有少数的报道用P-2凝胶柱对不保护的糖进行纯化,但是该操作比较费时间,凝胶柱价格高且只能做小量产物的纯化。
目前,部分保护的非天然糖分为两类:1,3-双酰化的非天然糖和1,6-双酰化的非天然糖。1,3-双酰化的非天然糖有多个报道的例子,1,6-双酰化的非天然糖只有1,6-Pr2GalNAz这一例。1,3-双酰化非天然糖的合成都是首先合成不带保护基的非天然糖,并将之作为起始原料,将糖的4号和6号位用丙叉进行保护后,对1号位和3号位的羟基进行酰化,最后脱除丙叉保护得1,3-双酰化非天然糖。该合成路线中,合成不带保护基的非天然糖原料时,面临以上陈述的问题,且从不带保护基的非天然糖合成1,3-双酰化的非天然糖时,总产率低。合成1,6-Pr2GalNAz时,需要用叠氮乙酸作为原料,叠氮乙酸的合成面临以上陈述的问题。
现阶段,在化学酶法标记和糖代谢标记领域所使用的非天然糖有两大类突出的问题:一是部分使用的非天然糖(如全乙酰化的糖)在代谢标记中会引入假阳性结果,需要对糖的结构进行优化设计,部分保护的糖研究刚刚起步,亟待推进;二是现有的方法合成这些非天然糖有很多的缺点,包括安全性、产率、大量制备难度高等。
针对第一类问题,所有的全乙酰化的非天然糖用于代谢标记时会引入S副反应,已有文献报道部分酰化的非天然糖既可以避免S副反应,同时能 提高非天然糖跨过细胞膜进入细胞内的效率。在公开报道的资料中,这些部分酰化的非天然糖包括1,3-Ac2GalNAz,1,3-Pr2GalNAz,1,3-Pr2ManNAz,1,3-Pr2GlcNAz,1,3-Pr2GlcNAl和1,6-Pr2GalNAz。其它的在糖代谢标记中有重要价值的新型部分酰化的糖未见报道,需要开发它们的合成方法,并开展它们的应用研究。
针对第二类问题,现有方法合成非天然糖有很多的缺点,需要发展新的合成方法,以更加经济、高效的方式合成有重要价值的非天然糖。以含有叠氮的非天然糖合成为例,合成过程中需要使用大过量的叠氮钠,存在爆炸的风险;反应需要加热,操作繁琐且不够安全;反应的产物需要反复的过柱子纯化,成本高且难以开展大规模的合成。
以上两类问题严重制约了非天然糖相关的应用研究,因此,需要开展新的策略,解决上述两大瓶颈问题。
发明内容
本发明的主要目的在于提供一种非天然糖及其合成方法和应用,以解决现有技术在非天然糖合成和应用方面的技术问题。
根据本发明的一个方面,提出一种合成非天然糖的方法,包括:室温下,将氨基糖的羟基进行全三甲基硅烷保护,选择性地暴露糖上的氨基,将所述氨基在室温下进行偶联、转化后,得到全三甲基硅烷保护的带有正交基团的非天然糖。
进一步地,将所述全三甲基硅烷保护的带有正交基团的非天然糖脱除三甲基硅烷保护基,得到不带保护基的非天然糖。
进一步地,所述不带保护基的非天然糖为GalNAz、GlcNAz、ManNAz、GalNAl、GlcNAl和ManNAl中的任意一种;
其中,GalNAz、GlcNAz、ManNAz的合成过程中,脱除三甲基硅烷保护基采用氢离子交换树脂脱除,终产物从溶剂中沉淀析出;
ManNAl的合成过程中,脱除三甲基硅烷保护基采用硅胶柱色谱纯化。
进一步地,所述全三甲基硅烷三甲基硅烷保护的带有正交基团的非天然糖的1号位和6号位的羟基被疏水基团保护,得到部分酰化的非天然糖。
进一步地,所述疏水基团为乙酰基、丙酰基、丁酰基和戊酰基中的任意一种。
进一步地,对于半乳糖型和葡萄糖型的全三甲基硅烷三甲基硅烷保护的带有正交基团的非天然糖,以吡啶为溶剂,加入四个当量的羧酸和大过量的对应酸酐,全三甲基硅烷保护的非天然糖的1号位和6号位的三甲基硅烷保护基被交换成对应的酯键,利用氢离子交换树脂脱除3号位和4号位的三甲基硅烷保护基后,得到1,6-双酰化非天然糖;
对于甘露糖型的全三甲基硅烷保护的带有正交基团的非天然糖,在二氯甲烷和甲醇的混合溶剂中,加入两个当量的醋酸铵选择性地同时脱除1号位和6号位的三甲基硅烷保护基,在吡啶中对1号位和6号位进行酯键保护,随后脱除糖的3号位和4号位的三甲基硅烷保护基,得到1,6-双酰化的甘露糖型非天然糖衍生物。
进一步地,所述全三甲基硅烷保护的带有正交基团的非天然糖的正交基团为叠氮、端炔、端烯、环丙烯、反式环辛烯、环辛炔中的任意一种。
根据本发明的另一方面,公开了一种用于代谢标记的部分酰化的非天然糖,为1,6-Ac2GalNAz、1,6-Pr2GalNAz、1,6-Bu2GalNAz、1,6-Ac2GlcNAz、1,6-Pr2GlcNAz、1,6-Bu2GlcNAz、1,6-Ac2ManNAz、1,6-Pr2ManNAz、1,6-Bu2ManNAz、1,6-Pr2ManNAl和1,6-Pr2ManNProc中的任意一种。
优选地,所述用于代谢标记的部分酰化的非天然糖采用上述的方法制成。
本发明还公开了一种糖代谢标记试剂盒,其包括上述的部分酰化的非天然糖。
本发明还公开了上述的一种部分酰化的非天然糖在糖代谢标记试剂盒中的应用,对HeLa细胞、3T3细胞、CHO细胞和MCF-7细胞中的任意一种细胞的糖代谢标记。
采用上述技术方案,本发明至少具有如下有益效果:
本发明提供的非天然糖及其合成方法和应用,提供了一种大量(10克量级)、高效合成不带保护基的非天然糖的方法。反应条件温和,操作简单方面,不需要色谱柱纯化。这些非天然糖包含不带保护基的非天然糖和部分羟基被保护的非天然糖,本发明公开的部分羟基被保护的非天然糖,兼顾了现有非天然糖的优点,既保证了非天然糖可以高效地被细胞所利用,也有效避免了非天然糖代谢过程中与蛋白中半胱氨酸发生S副反应。同时实现高效代谢标记。在细胞试验中,1,6-双酰化的非天然糖的使用浓度比不带保护基的非天然糖低一个数量级。
附图说明
为了更清楚地说明本发明实施例或现有技术中的技术方案,下面将对实施例或现有技术描述中所需要使用的附图作简单地介绍,显而易见地,下面描述中的附图仅仅是本发明的一些实施例,对于本领域普通技术人员来讲,在不付出创造性劳动的前提下,还可以根据这些附图获得其它的附图。
图1示出了本发明一实施例的1,6-双酰化糖与HeLa细胞的蛋白裂解液(cell lysates)或单蛋白进行孵育的反应结果图;
图2示出了本发明一实施例的1,6-双酰化糖在HeLa细胞中实现高效代谢标记的结果图;
图3示出了本发明一实施例的1,6-双酰化糖在不同细胞中的高效代谢标记图;
图4示出了本发明一实施例的1,6-Pr2GalNAz和1,6-Pr2ManNAz用于小鼠活体高效代谢标记图。
具体实施方式
为使本发明的目的、技术方案和优点更加清楚明白,以下结合具体实施例,并参照附图,对本发明实施例进一步详细说明。
需要说明的是,本发明实施例中所有使用“第一”和“第二”的表述均是为了区分两个相同名称非相同的实体或者非相同的参量,可见“第一”“第二”仅为了表述的方便,不应理解为对本发明实施例的限定,后续实施例对此不再一一说明。
本发明实施例公开了一种合成非天然糖的方法,包括:室温下,将氨基糖的羟基进行全三甲基硅烷保护,选择性地暴露糖上的氨基,将所述氨基在室温下进行偶联、转化后,得到全三甲基硅烷保护的带有正交基团的非天然糖。全三甲基硅烷保护的带有正交基团的非天然糖的正交基团为叠氮、端炔、端烯、环丙烯、反式环辛烯、环辛炔中的任意一种。将上述全三甲基硅烷保护的带有正交基团的非天然糖脱除三甲基硅烷保护基,得到不带保护基的非天然糖。其中,不带保护基的非天然糖可以为GalNAz、GlcNAz、ManNAz、GalNAl、GlcNAl和ManNAl中的任意一种;GalNAz、GlcNAz、ManNAz的合成过程中,脱除三甲基硅烷保护基采用氢离子交换树脂脱除,终产物从溶剂中沉淀析出;ManNAl的合成过程中,脱除三甲基硅烷保护基采用硅胶柱色谱纯化。
本发明一些实施例中,将上述全三甲基硅烷三甲基硅烷保护的带有正交基团的非天然糖的1号位和6号位的羟基被疏水基团保护,得到部分酰化的非天然糖。疏水基团可以为乙酰基、丙酰基、丁酰基和戊酰基中的任意一种。对于半乳糖型和葡萄糖型的全三甲基硅烷三甲基硅烷保护的带有正交基团的非天然糖,以吡啶为溶剂,加入四个当量的羧酸和大过量的对应酸酐,全三甲基硅烷保护的非天然糖的1号位和6号位的三甲基硅烷保护基被交换成对应的酯键,利用氢离子交换树脂脱除3号位和4号位的三甲基硅烷保护基后,得到1,6-双酰化非天然糖;对于甘露糖型的全三甲基硅烷保护的带有正交基团的非天然糖,在二氯甲烷和甲醇的混合溶剂中,加入两个当量的醋酸铵选择性地同时脱除1号位和6号位的三甲基硅烷保护基,在吡啶中对1号位和6号位进行酯键保护,随后脱除糖的3号位和4号位的三甲基硅烷保护基,得到1,6-双酰化的甘露糖型非天然糖衍生物(其也属于非天然糖)。
本发明一些实施例还公开了一种用于代谢标记的部分酰化的非天然糖,该非天然糖为六碳糖且是吡喃糖结构,在糖的一号位和六号位的羟基上具有酰基修饰。该非天然糖为1‐羟基和6‐羟基被疏水基团保护的非天然糖,其中,非天然糖一般为部分羟基被保护的六碳糖的衍生物。疏水基团为乙酰基、丙酰基、丁酰基或戊酰基。上述用于代谢标记的部分酰化的非天然糖采用上述的合成方法制成,即将糖的羟基进行全三甲基硅烷(TMS)保护,选择性地露出糖上的氨基;氨基通过偶联和化学转换,得到全TMS保护的带有正交基团的非天然糖。从全TMS保护的带有正交基团的出发,可以高效地合成不带保护基的非天然糖和部分酰基化的非天然糖。不带保护基的非天然糖为GalNAz、GlcNAz、ManNAz、ManNAl和ManNProc。部分酰化的非天然糖为1,6-Ac2GalNAz、1,6-Pr2GalNAz、1,6-Bu2GalNAz、1,6-Ac2GlcNAz、1,6-Pr2GlcNAz、1,6-Bu2GlcNAz、1,6-Ac2ManNAz、1,6-Pr2ManNAz、1,6-Bu2ManNAz、1,6-Pr2ManNAl和1,6-Pr2ManNProc中的任意一种。
本发明一些实施例还公开了一种糖代谢标记试剂盒,包括上述的部分酰化的非天然糖。该部分酰化的非天然糖的1号位和6号位羟基被保护。该部分酰化的非天然糖为1号位和6号位被保护的六碳糖类似物。该部分酰化的非天然糖为1号位和6号位的羟基被疏水基团保护的非天然糖。其可以实现对HeLa细胞、3T3细胞、CHO细胞和MCF-7细胞中的任意一种细胞的糖代谢标记。
本发明的上述实施例是基于全TMS(三甲基硅烷)保护的策略,开发了一种大量、高效合成不带保护基的非天然糖(目标化合物类别1)以及高效率合成1,6-双酰化非天然糖的方法(目标化合物类别2)。
总体上,本发明的实施例从含六碳原子的氨基糖出发,将糖上的所有羟基进行TMS保护,选择性地露出糖上的氨基,并进一步偶联、转化,得到全TMS保护的带有正交基团的非天然糖。全TMS保护方法选择性地露出氨基时,一方面可以避免不做TMS保护时糖上的羟基参与或者干扰后续的偶联反应;另一方面,在偶联时,反应可以在不含羟基的溶剂中进行, 避免了溶剂上的羟基可能参与或者干扰偶联反应(羟基不做TMS保护时,氨基糖只能在含羟基的溶剂中溶解,如水和甲醇)。因此,全TMS保护方法中,用于和糖上氨基进行偶联的分子需要的量少(一个或略多于一个当量即可),偶联效率高(几乎是定量反应)且使用的溶剂易于减压蒸除掉(一般是二氯甲烷为偶联溶剂)。全TMS保护的带有正交基团的非天然糖,是本专利中合成目标化合物类别1和目标化合物类别2重要的中间体。
上述方法所得全TMS保护的非天然糖,无需柱色谱纯化,可利用氢离子交换树脂脱除TMS保护基,得到不带保护基的非天然糖(目标化合物类别1,已成功大量合成了GalNAz、GlcNAz、ManNAz和ManNAl)。需要特别指出,该合成方法用于合成GalNAz、GlcNAz和ManNAz时,中间没有任何色谱纯化步骤,终产物从乙醇中以沉淀方式析出。合成ManNAl时,无法采用析出沉淀的方式,但可以通过一次硅胶柱色谱快速纯化干净。
另外,上述方法所得全TMS保护的非天然糖,可以通过一次简单的硅胶柱纯化后,经过两步简单的反应得到1,6-双酰化的非天然糖。针对不同的糖开发了两种技术路线:
对于半乳糖型和葡萄糖型的全TMS保护的非天然糖而言,以吡啶为溶剂,加入四个当量的羧酸和大过量的对应酸酐,全TMS保护的非天然糖的1号位和6号位的TMS被交换成对应的酯键,利用氢离子交换树脂脱除3号位和4号位的TMS保护基后,得1,6-双酰化非天然糖;
对于甘露糖型的全TMS保护的非天然糖,在二氯甲烷和甲醇的混合溶剂中,加入两个当量的醋酸铵选择性地同时脱除糖的1号位和6号位的TMS保护基,在吡啶中对1号位和6号位进行酯键保护,随后脱除糖的3号位和4号位的TMS保护基,得到1,6-双酰化的甘露糖型非天然糖衍生物。
基于上述合成策略,可以高效率地合成1,6-双酰化非天然糖(目标化合物类别2),包括1,6-Ac2GalNAz、1,6-Pr2GalNAz、1,6-Bu2GalNAz、1,6-Ac2GlcNAz、1,6-Pr2GlcNAz、1,6-Bu2GlcNAz、1,6-Ac2ManNAz、1,6-Pr2ManNAz、1,6-Bu2ManNAz、1,6-Pr2ManNAl和1,6-Pr2ManNProc。
需要特别指出,有文献从全TMS保护的GalNAz出发,合成了1,6-Pr2GalNAz这一种糖,但是该方法合成全TMS保护的GalNAz时,需要使用叠氮乙酸作为原料。如前文所述,叠氮乙酸的合成,存在爆炸的风险。本发明实施例所公开的合成方法中,避免了需要合成叠氮乙酸的问题,并成系统地拓展到其它糖。
从技术角度,相比现有合成方法,本发明实施例所公开的合成方法的优势在于:全TMS保护的糖衍生物有较小的极性,在很多低极性的溶剂(比如二甲基甲酰胺、二氯甲烷、乙酸乙酯、石油醚、乙腈等)中有很好的溶解度,可以方便地进行各种化学转化(比如将卤素取代为叠氮),得到各种全TMS保护且含正交基团的非天然糖。以上合成方法中,所有反应均为室温反应,没有色谱纯化的过程,可以开展大规模的合成(10克级)。在合成含有叠氮的非天然糖过程中,叠氮钠只需要一个当量,用量小,操作安全。
从应用角度,合成的1,6-双酰化的糖容易穿过细胞膜,进入细胞中,在糖代谢标记试验中,能有效避免S副反应,而且还能保持较高的代谢效率。
总之,本发明的主要目的在于提供一种大量、高效率合成非天然糖的方法,并开展其应用研究。本发明中新报道的1,6-双酰化的非天然糖可以提高糖代谢标记的效率,同时不引入S副反应。
需要说明的是,在不冲突的情况下,本申请中的实施例及实施例中的特征可以相互组合。
非天然糖:对天然单糖进行化学修饰,连接叠氮、炔基等生物正交基团。非天然糖能够被细胞摄取,通过天然糖代谢通路整合到糖链中,然后通过生物正交反应对聚糖进行标记、成像或富集。
生物正交反应:指那些能够在活体细胞或组织中,能够在不干扰生物自身生化反应条件下,可以进行的化学反应。用于研究核酸、蛋白质、糖或脂质等生物大分子。
本发明解决了糖化学酶法标记和代谢标记中,已报道的非天 然糖化学合成的难题,并公开了一类结构新颖的1,6-双酰化的非天然糖。
本申请对现有合成非天然糖的方法进行了研究和改进,发展了基于全TMS保护的策略,开发了一种大量合成不带保护基的非天然糖的方法;同时,从全TMS保护的非天然糖出发,可以高效率地合成1,6-双酰化的非天然糖。1,6-双酰化的非天然糖容易穿过细胞膜,进入细胞中,在糖代谢标记试验中,能有效避免S副反应,而且还能保持较高的代谢效率。
具体地,本申请是从含六碳原子的氨基糖出发,将糖上的所有羟基进行TMS保护,选择性地露出糖上的氨基。氨基和各种小分子偶联后,得到各种全TMS保护的酰基被取代的氨基糖衍生物。该全TMS保护的糖衍生物有较小的极性,在很多低极性的溶剂(比如二甲基甲酰胺、二氯甲烷、乙酸乙酯、石油醚、乙腈等)中有很好的溶解度,可以进行各种化学转化(比如将卤素取代为叠氮),得到各种全TMS保护的非天然糖(该全TMS保护的非天然糖含有叠氮或者是炔基等正交基团)。在甲醇中,利用氢离子交换树脂脱除TMS保护基,过滤,滤液浓缩后,加入乙醇,析出的固体为不带保护基的非天然糖。以上方法合成不带保护基的非天然糖过程中,所有反应均为室温反应,没有色谱纯化的过程,可以开展大规模的合成(10克级)。在合成含有叠氮的非天然糖过程中,叠氮钠只需要一个当量,用量小,操作安全。基于该TMS保护的策略,申请人大量合成了GalNAz、GlcNAz、ManNAz和ManNAl。
在上述合成不带保护基的非天然糖过程中,含正交基团的全TMS保护的非天然糖是一个重要的中间体,从该中间体出发,可以经过两步简单的反应得到1,6-双酰化的非天然糖。对于半乳糖型和葡萄糖型的全TMS保护的非天然糖而言,以吡啶为溶剂,加入四个当量的羧酸和大过量的对应酸酐,全TMS保护的非天然糖的1号位和6号位的TMS被交换成对应的酯键,脱除3号位和4 号位的TMS保护基后,得1,6-双酰化非天然糖;对于甘露糖型的全TMS保护的非天然糖,在二氯甲烷和甲醇的混合溶剂中,利用两个当量的醋酸铵选择性地同时脱除糖的1号位和6号位的TMS保护基,在吡啶中对1号位和6号位进行酯键保护,随后脱除糖的3号位和4号位的TMS保护基,得到1,6-双酰化的甘露糖型非天然糖衍生物。
在糖代谢标记试验中,发现1,6-双酰化的糖都不和蛋白质发生S副反应;同时,1,6-双酰化的糖都具有较高的代谢标记效率。另外,和不带保护基的糖相比,不同的酯键保护基提高代谢标记效率的幅度有所不同,比如乙酰基相比丙酰基,提升的效率幅度不大,丁酰基修饰和丙酰基修饰能显著地提升非天然糖代谢效率。最后,1,6-双丙酰化的糖还可以用于小鼠活体高效代谢标记。
在本发明的一些实施例中,基于全TMS的策略合成不带保护基的非天然糖时,所含的正交基团不局限于叠氮和炔基,含有其它正交基团的不带保护基的非天然糖都可以利用该策略进行合成。其它的正交基团包括但不限于端烯、环丙烯、反式环辛烯和环辛炔。因此,这些不保护的非天然糖的合成均受到该专利的保护。
在本发明的一些实施例中,基于全TMS的策略合成不带保护基的非天然糖时,所适用的底物不仅仅局限于半乳糖胺衍生物、葡萄糖胺衍生物和甘露糖胺衍生物,其它的含有氨基的糖都可以作为该类型合成的底物。因此,这些不保护的非天然糖的合成均受到该专利的保护。
在本发明的一些实施例中,基于全TMS的策略合成部分酰化的非天然时,所使用的酰基不仅限于乙酰基、丙酰基和丁酰基,其它的酰基也可以用过本申请的方法引入。因此,其它酰化保护的部分酰化的非天然糖也受到该专利的保护。
在本申请第一种典型的实施方式中,提供简单高效方法,合成不带保护基的非天然糖。具体为GalNAz、GlcNAz、ManNAz 和ManNAl,并合成上述部分酰化的非天然糖。
在本申请第二种典型的实施方式中,提供了一种糖代谢标记试剂盒,试剂盒包括上述任一种部分酰化的非天然糖。
在本申请第三种典型的实施方式中,提供了上述任一种的部分酰化的非天然糖或者上述试剂盒在糖代谢标记中的应用。采用本申请的部分酰化的非天然糖代谢标记,不仅能够具有较高的代谢效率,而且不与蛋白中的半胱氨酸发生副反应。在一种优选的实施例中,上述应用包括对如下任一种细胞的糖代谢标记:HeLa细胞、MCF-7细胞、CHO细胞和3T3细胞。在一种优选的实施例中,利用1,6-Pr2GalNAz和1,6-Pr2ManNAz对小鼠活体进行代谢标记。
现有技术合成部分羟基被保护的含叠氮的非天然糖时,需要用到叠氮钠,有爆炸风险,尤其是大量合成时,如10克级别,爆炸风险更高。本发明中合成1,6-Pr2GalNAz的方法比文献已报道的合成方法更加高效和安全。和其它已经报道的1,3-双酰化的非天然糖相比,基于蛋白质巯基上的S糖化修饰副反应的机理和部分酰化糖的稳定性而言,本发明的1,6-双酰化的非天然糖是更好的选择,且本发明中合成1,6-双酰化糖时,是从全TMS保护的糖出发,合成更加简单、高效。
下面结合具体的实施例来进一步说明本申请的有益效果。
实施例1:GalNAz、GlcNAz和ManNAz的合成。
GalNAz、GlcNAz和ManNAz的合成见合成路线一:
其中,Ⅰ,Ⅱ,Ⅲ,Ⅳ步骤条件分别如下:
GalN盐酸盐(化合物1a,100毫摩尔,21.5克)分散在200 毫升的无水乙腈中,分批次加入40.3克的HMDS(250毫摩尔),室温反应3小时。过滤,滤液真空浓缩得化合物1b,油状物,不纯化直接用于下一步。
27.6克溴乙酸(200毫摩尔)和25.3克HOSU(220毫摩尔)溶于220毫升的二氯甲烷,溶液降温至-5℃。将含45.3克(220毫摩尔)DCC的二氯甲烷溶液(50毫升)滴加到上述的溶液中,历时1小时。滴加完毕,反应体系升温至室温并反应2小时。过滤,滤液真空浓缩得残留物,残留物用200毫升的正己烷处理并充分搅拌得混合物。该混合物过滤,滤饼用正己烷洗涤得白色固体,经真空干燥后得36.0克的粗产物2,5-dioxopyrrolidin-1-yl2-bromoacetate(4a),化合物4a不纯化直接用于下一步反应。上一步得到的全部化合物1b用200毫升的二氯甲烷溶解,冰水浴降温后,加入33.3克的4a(140毫摩尔)。反应室温搅拌2小时,真空浓缩至恒重,加入200毫升的正己烷和20毫升的乙酸乙酯,搅拌。沉淀过滤,滤液旋干后得黄色油状物,为化合物1c,1c不纯化直接用于下一步。
上一步得到的1c溶于150毫升的DMF,加入6.8克(100毫摩尔)的叠氮钠,室温搅拌过夜。混合物用200毫升的乙酸乙酯稀释,有机相用水洗涤,水相用100毫升的乙酸乙酯萃取一次。有机相用饱和的食盐水洗涤两次,无水硫酸钠干燥。过滤,滤液真空浓缩后得黄色油状物1d,化合物1d不纯化直接用于下一步。
1d溶于150毫升的甲醇,加入10克的氢离子交换树脂(Dowex),室温搅拌2小时,TLC显示反应完毕。反应过滤,滤液旋干,加入200毫升的乙醇搅拌,过滤,收集滤饼,真空干燥后得11.6克的产物1e,四步产率44%,产物为α构型。
化合物1e(GalNAz)的核磁检测数据为:1H NMR(500MHz,DMSO-d6)7.78(d,J=8.7Hz,1H),6.43(dd,J=4.4,1.2Hz,1H),4.95(t,J=3.9Hz,1H),4.51(t,J=5.6Hz,1H),4.47(d,J=4.3Hz, 1H),4.45–4.40(m,2H),4.01(ddd,J=11.5,8.7,3.4Hz,1H),3.85(d,J=15.4Hz,1H),3.83–3.79(m,1H),3.80(d,J=15.4Hz,1H),3.76–3.70(m,1H),3.68–3.58(m,1H),3.58–3.50(m,1H),3.43(dd,J=10.7,6.2Hz,1H)。13C NMR(126MHz,DMSO-d6)δ167.7,90.9,70.6,68.3,67.4,60.7,50.7,50.6。
化合物2e(GlcNAz,9.6克)按照上述实施例1中合成GalNAz的方法从21.5克(100毫摩尔)的GlcN盐酸盐为原料得到。四步产率37%。产物为端基异构体混合物,α/β,5/1。
化合物2e(GlcNAz)的核磁检测数据为:1H NMR(α异构体,500MHz,Methanol-d4)δ5.11(d,J=3.5Hz,1H),3.95(d,J=15.8Hz,1H),3.92(s,1H),3.87(dd,J=10.7,3.7Hz,1H),3.83–3.76(m,2H),3.74–3.67(m,2H),3.38(t,J=9.2Hz,1H)。13C NMR(126MHz,Methanol-d4)δ170.9,170.4,96.8,92.5,78.1,75.8,73.2,72.8,72.4,72.2,62.9,62.8,59.0,55.9,53.2,52.9。
化合物3e(ManNAz,10.8克)按照上述实施例1中合成GalNAz的方法,从21.5克(100毫摩尔)的ManN盐酸盐为原料得到得到。四步产率41%。产物为端基异构体混合物,α/β,2/1。
化合物3e(ManNAz)核磁检测数据为:1H NMR(500MHz,Methanol-d4)δ5.03(d,J=1.6Hz,1H),4.29(dd,J=4.7,1.7Hz,1H),4.02(dd,J=9.7,4.7Hz,1H),3.93(s,1H),3.89(d,J=15.8Hz,1H),3.86–3.74(m,3H),3.55(t,J=9.6Hz,1H)。13C NMR(151MHz,Methanol-d4)δ171.5,170.6,94.6,94.5,78.1,74.1,73.2,70.2,68.3,68.0,62.0,61.9,55.7,55.0,52.6,52.4,49.6。
实施例2:ManNAl的合成。
ManNAl的合成见合成路线二:
其中,Ⅰ,Ⅱ步骤条件分别如下:
2.16克(22毫摩尔)戊炔酸和2.78克(24.2毫摩尔)的HOSU溶于50毫升的二氯甲烷中,溶液降温至-5℃,在上述溶液中,滴加4.98克(24.4毫摩尔)DCC的二氯甲烷溶液(20毫升),历时20分钟。反应升温到室温,继续搅拌2小时,反应完毕。过滤,滤液浓缩后得产物4b(2,5-dioxopyrrolidin-1-yl pent-4-ynoate),4b不纯化直接用于下一步。
依据实施例1中的方法,从18.7毫摩尔的ManN盐酸盐(3a)出发合成化合物3b粗品,该3b粗品溶于50毫升的二氯甲烷中,冰水浴降温到0℃,往上述溶液中滴加上一步反应得到的4b。反应在室温搅拌2小时,反应完毕后真空浓缩得残留物。往残留物中加入100毫升的正己烷,搅拌过滤,滤液真空浓缩得黄色油状物3f,不纯化直接用于下一步。
上一步得到的3f溶于50毫升的甲醇,加入两克氢离子交换树脂。反应室温搅拌2小时,反应完全。过滤,滤液真空浓缩得残留物,该残留物经硅胶柱纯化得3.06克化合物3g(ManNAl)。三步产率64%。产物为端基异构体混合物,α/β,3/1。
化合物3g的核磁检测数据为:1H NMR(500MHz,Methanol-d4)δ5.01(d,J=1.6Hz,1H),4.29(dd,J=4.6,1.7Hz,1H),4.00(dd,J=9.7,4.7Hz,1H),3.87–3.74(m,3H),3.58(t,J=9.7Hz,1H),3.35(s,1H),2.59–2.42(m,4H),2.26(t,J=2.3Hz,1H)。13C NMR(126MHz,Methanol-d4)δ175.5,174.5,94.8,94.7,83.8,83.5,78.0,74.3,73.2,70.4,70.0,69.9,68.3,67.9,62.0,61.9,55.6,54.9,35.9,35.72,35.67,15.42,15.40。
实施例3:1,6-Ac2GalNAz、1,6-Pr2GalNAz、1,6-Bu2GalNAz、6-Ac2GlcNAz、1,6-Pr2GlcNAz和1,6-Bu2GlcNAz的合成。
1,6-Ac2GalNAz、1,6-Pr2GalNAz、1,6-Bu2GalNAz、6-Ac2GlcNAz、1,6-Pr2GlcNAz、1,6-Bu2GlcNAz的合成见合成路线三:
其中,Ⅰ,Ⅱ步骤条件分别如下:
步骤Ⅰ,合成1f,1g,1h,2f,2g和2h的一般方法:0.5毫摩尔的1d或者2d溶于1毫升的吡啶,氮气保护下加入0.75毫升的酸酐和2.0毫摩尔的对应羧酸。室温反应20小时,,反应液用乙酸乙酯稀释,有机相依次用1摩尔每升的稀盐酸、饱和碳酸氢钠溶液和饱和食盐水洗涤。有机相用无水硫酸钠干燥,,干燥完毕过滤,滤液真空浓缩,残留物用硅胶柱进行纯化得对应产物。
1d。1d是从1a合成1e的中间体,可以利用硅胶柱以石油醚和乙酸乙酯为洗脱剂进行快速色谱纯化。从20毫摩尔的1a出发可以合成4.1克的1d,三步产率37%。产物构型。
化合物1d的核磁检测数据为:1H NMR(500MHz,Chloroform-d)δ6.29(d,J=8.0Hz,1H),5.16–5.10(m,1H),4.10(dd,J=10.4,2.8Hz,1H),3.92(s,2H),3.87(d,J=2.8Hz,1H),3.68–3.62(m,1H),3.62–3.55(m,1H),3.55–3.49(m,1H),3.47–3.43(m,1H),0.13(s,9H),0.12(s,9H),0.12(s,9H),0.11(s,9H)。13C NMR(126MHz,Chloroform-d)δ166.70,94.63,75.17,71.24, 70.63,61.04,57.42,53.18,0.76,0.44,0.30,-0.40。
2d。2d的合成和纯化采用和1d类似的方法,从20毫摩尔的2a出发合成5.91克的2d,三步产率54%。产物构型。
化合物2d的核磁检测数据为:1H NMR(400MHz,Chloroform-d)δ6.36(d,J=10.1Hz,1H),5.01(d,J=3.5Hz,1H),4.07–3.94(m,3H),3.76–3.64(m,3H),3.63–3.56(m,2H),0.17(s,9H),0.15(s,9H),0.12(s,9H),0.09(s,9H)。13C NMR(126MHz,Chloroform-d)δ166.24,92.59,74.04,72.71,72.07,61.75,54.53,53.11,1.05,0.90,-0.13,-0.21。
1f。1f的合成依据上述实施例3中的一般方法合成得到。产率86%。产物为端基异构体,α/β,1/1.56。
1f的核磁检测数据为:1H NMR(β异构体,500MHz,Chloroform-d)δ6.20(d,J=8.8Hz,1H),5.90(d,J=8.6Hz,1H),4.18(d,J=2.0Hz,1H),4.17–4.13(m,1H),4.04(dt,J=10.5,8.7Hz,1H),3.94(dd,J=11.0,2.7Hz,3H),3.83(d,J=2.7Hz,1H),3.78(td,J=6.3,0.9Hz,1H),2.10(s,3H),2.07(s,3H),0.14(s,9H),0.14(s,9H)。1H NMR(α端基异构体,500MHz,Chloroform-d)δ6.16(d,J=3.7Hz,1H),6.03(d,J=9.4Hz,1H),4.63(td,J=10.0,3.6Hz,1H),4.13(d,J=6.4Hz,2H),4.05(d,J=16.8Hz,1H),3.99(d,J=16.6Hz,1H),3.98(t,J=6.3Hz,1H),3.89(d,J=1.8Hz,1H),3.81(dd,J=10.6,2.6Hz,1H),2.15(s,3H),2.07(s,3H),0.18(s,9H),0.15(s,9H)。13C NMR(α/β,126MHz,Chloroform-d)δ170.73,170.69,169.7,169.2,166.8,166.3,92.3,92.1,73.55,71.9,71.2,71.1,70.8,69.6,63.2,63.2,52.9,52.8,52.8,48.3,21.1,21.0,20.9,0.63,0.55,0.4,0.36。
1g。1g依据上述实施例3中一般方法合成得到。产率89%。产物为端基异构体,α/β,1.25/1。
化合物1g的核磁检测数据为:1H NMR(α和β端基异构体混合物,500MHz,Chloroform-d)δ6.21(d,J=8.9Hz,1H),6.18(d,J=3.6Hz,1H),6.04(d,J=9.5Hz,1H),5.90(d,J=8.6Hz,1H),4.64(td,J=10.1,3.6Hz,1H),4.19(d,J=6.3Hz,2H),4.15(d,J=6.5Hz,2H),4.11–4.02(m,2H),4.02–3.96(m,2H),3.94(d,J=5.4Hz,2H),3.91–3.88(m,1H),3.85–3.80(m,2H),3.80–3.76(m,1H),2.46–2.30(m,8H),1.23–1.09(m,12H),0.18(s,9H),0.15(s,19H),0.14(s,8H)。13C NMR(α和β端基异构体混合物,126MHz,Chloroform-d)δ174.2,174.2,173.2,172.6,166.8,166.2,92.3,91.9,73.6,72.0,71.2,71.1,70.8,69.7,63.0,62.9,52.9,52.8,52.8,48.3,27.8,27.6,27.55,27.52,9.2,9.17,9.14,8.9,0.63,0.56,0.4,0.3。
1h。1h依据上述实施例3中一般方法合成得到。产率70%。产物为端基异构体混合物,α/β,2.55/1。
化合物1h的核磁检测数据为:1H NMR(500MHz,Chloroform-d)δ6.18(d,J=3.7Hz,1H),6.02(d,J=9.5Hz,1H),4.63(td,J=10.0,3.6Hz,1H),4.03(d,J=16.9Hz,1H),4.00(s,1H),3.98–3.95(m,1H),3.92(d,J=4.2Hz,1H),3.90(d,J=2.6Hz,1H),3.83(dd,J=4.9,2.6Hz,1H),2.36(t,J=7.3Hz,2H),2.28(t,J=7.3Hz,2H),1.73–1.66(m,2H),1.66–1.59(m,2H),0.99(t,J=7.3Hz,3H),0.94(t,J=7.4Hz,3H),0.17(s,9H),0.14(s,9H)。13C NMR(126MHz,Chloroform-d)δ173.1,173.0,172.0,171.4,166.5,166.0,91.8,91.5,73.2,71.8,71.0,70.9,70.5,69.4,62.8,62.5,52.6,52.4,52.4,48.0,36.0,35.8,35.8,35.4,18.2,18.2,18.0,17.9,13.40,13.37,13.3,13.2,0.33,0.26,0.1,0.01。
2f。2f依据上述实施例3中一般方法合成得到。产率62%。α异构体。
化合物2f的核磁检测数据为:1H NMR(500MHz,Methanol-d4)δ5.97(d,J=3.9Hz,1H),4.37(dd,J=12.1,2.3Hz,1H),4.18(dd,J =10.1,3.9Hz,1H),4.07(dd,J=12.1,4.3Hz,1H),3.89–3.84(m,3H),3.82(dd,J=10.1,8.1Hz,1H),3.69(dd,J=9.7,8.1Hz,1H),2.16(s,3H),2.08(s,3H),0.19(s,9H),0.17(s,9H)。13C NMR(126MHz,Methanol-d4)δ172.6,171.4,170.8,92.4,75.1,74.0,73.4,64.4,54.5,53.0,21.1,21.0,1.4,1.2。
2g。2g依据上述实施例3中一般方法合成得到。产率62%。α异构体。
化合物2g的核磁检测数据为:1H NMR(500MHz,Chloroform-d)δ6.35(d,J=9.9Hz,1H),6.06(d,J=3.5Hz,1H),4.39(dd,J=12.1,2.7Hz,1H),4.28(td,J=9.6,3.5Hz,1H),4.10(dd,J=12.1,4.8Hz,1H),4.06(d,J=16.8Hz,1H),4.00(d,J=16.8Hz,1H),3.89–3.80(m,1H),3.75(dd,J=9.3,7.6Hz,1H),3.68(dd,J=8.5,7.6Hz,1H),2.42(qd,J=7.5,0.9Hz,2H),2.36(qd,J=7.6,2.9Hz,2H),1.19(t,J=7.5Hz,3H),1.14(t,J=7.5Hz,3H),0.16(s,9H),0.16(s,9H)。13C NMR(151MHz,Chloroform-d)δ173.8,172.2,166.0,90.4,73.2,72.9,71.3,62.2,52.4,51.8,27.4,27.2,8.82,8.78。
2h。2h依据上述实施例3中一般方法合成得到。产率44%。α异构体。
化合物2h的核磁检测数据为:1H NMR(500MHz,Chloroform-d)δ6.32(d,J=9.9Hz,1H),6.07(d,J=3.5Hz,1H),4.40(dd,J=12.1,2.7Hz,1H),4.28(td,J=9.7,3.6Hz,1H),4.08(dd,J=12.1,4.9Hz,1H),4.06(d,J=16.8Hz,1H),4.00(d,J=16.8Hz,1H),3.83(ddd,J=7.8,4.8,2.6Hz,1H),3.75(dd,J=9.4,7.7Hz,1H),3.67(dd,J=8.7,7.7Hz,1H),2.37(t,J=7.3Hz,2H),2.31(td,J=7.4,3.7Hz,2H),1.72–1.63(m,4H),0.99(t,J=7.4Hz,3H),0.95(t,J=7.4Hz,3H),0.17(s,9H),0.16(s,9H)。13C NMR(126MHz,Chloroform-d)δ172.4,170.8,165.5,89.8,72.6,70.8, 61.6,51.8,51.3,35.3,35.2,17.6,17.5,12.8,12.7,1.4,1.2。
合成1i,1j,1k,2i,2j和2k的一般方法:1f,1g,1h,2f,2g或者2h的甲醇溶液中,加入适量的氢离子交换树脂,室温搅拌。TLC显示反应完全后,过滤,滤液真空浓缩,残留物经硅胶柱纯化得对应产物。
1i。1i依据上述实施例3中一般方法合成得到。产率52%,α/β,2/1。
化合物1i的核磁和质谱检测数据为:1H NMR(α异构体,500MHz,Methanol-d4)δ6.15(d,J=3.7Hz,1H),4.42(dd,J=11.1,3.7Hz,1H),4.22(d,J=3.3Hz,1H),4.21(d,J=1.5Hz,1H),4.11(ddd,J=6.8,5.1,1.3Hz,1H),3.94(dd,J=3.2,1.3Hz,1H),3.93–3.81(m,4H),2.12(s,3H),2.04(s,3H)。13C NMR(α和β异构体混合物,126MHz,Methanol-d4)δ171.2,169.9,169.7,169.6,169.5,92.8,91.0,73.6,70.78,70.77,68.4,69.0,67.3,63.4,63.3,51.8,51.6,51.3,49.1,19.4,19.3.HRMS(ESI)理论分子量C12H19N4O8[M+H]+347.12029,检测分子量347.11959。
1j。1j依据上述施例3中一般方法合成得到。产率83%,α/β,1.45/1。
化合物1j的核磁和质谱检测数据为:1H NMR(α异构体,500MHz,Methanol-d4)δ6.16(d,J=3.7Hz,1H),4.41(dd,J=11.1,3.7Hz,1H),4.10(ddd,J=6.8,5.1,1.3Hz,1H),3.94(dd,J=3.3,1.3Hz,1H),3.90(d,J=15.8Hz,1H),3.88(dd,J=11.1,3.2Hz,1H),3.83(d,J=15.8Hz,1H),2.42(qd,J=7.6,1.9Hz,2H),2.33(q,J=7.5Hz,2H),1.14(t,J=7.5Hz,3H),1.10(t,J=7.6Hz,3H)。13C NMR(126MHz,Methanol-d4)δ175.71,175.68,174.4,174.2,170.7,170.6,94.0,92.0,74.8,72.0,71.9,69.6,69.1,68.6,64.4,64.2,53.0,52.8,52.5,50.4,28.0,28.0,27.97,27.94,9.2,9.14,9.06,8.9。HRMS(ESI)理论分子量C14H23N4O8[M+H]+375.15159,检测分子量 375.15076。
1k。1k依据上述施例3中一般方法合成得到。产率69%,α/β,2.67/1。
化合物1k的核磁和质谱检测数据为:1H NMR(α异构体,500MHz,Methanol-d4)δ6.17(d,J=3.7Hz,1H),4.41(dd,J=11.1,3.7Hz,1H),4.34–4.19(m,3H),4.09(ddd,J=7.4,4.7,1.3Hz,1H),3.94(dd,J=3.2,1.3Hz,1H),3.92–3.80(m,5H),2.39(t,J=7.3Hz,2H),2.35–2.27(m,4H),1.72–1.57(m,6H),1.00–0.91(m,9H)。13C NMR(126MHz,Methanol-d4)δ173.7,173.6,172.3,172.2,169.5,169.4,92.7,90.7,73.6,70.90,70.86,68.5,68.0,67.4,63.4,63.0,51.8,51.6,51.3,49.2,35.5,35.42,35.41,18.00,17.96,17.8,12.5,12.5,12.4。HRMS(ESI)理论分子量C16H27N4O8[M+H]+403.18289,检测分子量403.18234。
2i。2i依据上述施例3中一般方法合成得到。产率69%。α异构体。
化合物2i的核磁和质谱检测数据为:1H NMR(500MHz,Methanol-d4)δ6.10(d,J=3.7Hz,1H),4.33(dd,J=12.1,2.3Hz,1H),4.23(dd,J=12.1,5.2Hz,1H),4.04(dd,J=10.8,3.6Hz,1H),3.90(d,J=15.8Hz,1H),3.87–3.80(m,2H),3.73(dd,J=10.8,8.8Hz,1H),3.45(dd,J=10.2,8.8Hz,1H),2.13(s,3H),2.06(s,3H)。13C NMR(126MHz,Methanol-d4)δ172.7,171.1,170.8,91.9,73.5,72.0,71.8,64.4,54.4,52.6,20.7,20.6。HRMS(ESI)理论分子量C12H19N4O8[M+H]+347.12029,检测分子量347.11922。
2j。2j依据上述施例3中一般方法合成得到。产率79%。α异构体。
化合物2j的核磁和质谱检测数据为:1H NMR(500MHz,Methanol-d4)δ6.12(d,J=3.6Hz,1H),4.35(dd,J=12.0,2.2Hz, 1H,C6-Ha),4.23(dd,J=12.0,5.4Hz,1H,C6-Hb),4.04(dd,J=10.8,3.7Hz,1H),3.90(d,J=15.9Hz,1H,CH2a),3.87–3.80(m,2H,C5-H),3.73(dd,J=10.8,8.8Hz,1H),3.45(dd,J=10.1,8.8Hz,1H),2.45(qd,J=7.5,1.1Hz,2H),2.36(q,J=7.6Hz,2H),1.15(t,J=6.8Hz,3H),1.12(t,3H)。13C NMR(126MHz,Methanol-d4)δ175.8,174.2,170.6,91.6,73.3,71.9,71.6,64.1,54.3,52.4,28.0,9.2,9.0。HRMS(ESI)理论分子量C14H23N4O8[M+H]+375.15159,检测分子量375.15102。
2k。2k依据上述施例3中一般方法合成得到。产率78%。α异构体。
化合物2k的核磁和质谱检测数据为:1H NMR(500MHz,Methanol-d4)δ6.12(d,J=3.6Hz,1H),4.37(dd,J=11.9,2.2Hz,1H),4.21(dd,J=12.0,5.7Hz,1H),4.03(dd,J=10.8,3.7Hz,1H),3.90(d,J=15.8Hz,1H),3.85–3.80(m,2H),3.73(dd,J=10.8,8.8Hz,1H),3.43(dd,J=10.1,8.8Hz,1H),2.40(td,J=7.2,1.2Hz,2H),2.32(t,J=7.3Hz,2H),1.72–1.66(m,2H),1..67–0.96(m,8H),0.98(t,J=7.4Hz,3H),0.95(t,J=7.4Hz,3H)。13C NMR(126MHz,Methanol-d4)δ174.9,173.3,170.5,91.4,73.4,71.9,71.7,64.1,54.3,52.4,36.6,36.6,19.2,19.1,13.72,13.68。HRMS(ESI)理论分子量C16H27N4O8[M+H]+403.18289,检测分子量403.18225。
实施例4:1,6-Ac2ManNAz、1,6-Pr2ManNAz、1,6-Bu2ManNAz、1,6-Pr2ManNAl和1,6-Pr2ManNProc的合成。
1,6-Ac2ManNAz、1,6-Pr2ManNAz、1,6-Bu2ManNAz、1,6-Pr2ManNAl和1,6-Pr2ManNProc的合成见合成路线四:
其中,Ⅰ,Ⅱ步骤条件分别如下:
3d。3d的合成和纯化采用和1d类似的方法,从20毫摩尔的3a出发合成4.1克的3d,三步产率37%。α异构体。
化合物3d的核磁检测数据为:1H NMR(500MHz,Chloroform-d)δ6.43(d,J=7.9Hz,1H),5.10(d,J=1.5Hz,1H),4.15–4.06(m,2H),4.00(d,J=16.5Hz,1H),3.95(d,J=16.3Hz,1H),3.77(dd,J=11.3,3.4Hz,1H),3.72–3.60(m,3H),0.16(s,9H),0.16(s,9H),0.15(s,9H),0.12(s,9H)。13C NMR(126MHz,Chloroform-d)δ166.77,93.39,72.77,70.10,68.85,61.65,55.60,53.00,0.74,0.37,-0.04,-0.25。
3f。3.95克(8.44毫摩尔,1.0当量)3b溶于50毫升的无水二氯甲烷,加入1.65克(8.44毫摩尔,1.0当量)2,5-dioxopyrrolidin-1-yl pent-4-ynoate(4b)。反应室温搅拌2小时,TLC显示反应完全,溶剂旋蒸后得残留物,经硅胶柱纯化得4.40克产物3f。产率95%。α异构体。
化合物3f的核磁测试结果如下:1H NMR(500MHz,Chloroform-d)δ5.78(d,J=7.1Hz,1H),5.14(d,J=1.4Hz,1H),4.11–4.05(m,2H),3.73(dd,J=11.4,4.2Hz,1H),3.69(dd,J=11.4,2.1Hz,1H),3.65(ddd,J=9.6,4.2,2.1Hz,1H),3.55(t,J=9.0Hz,1H),2.55–2.48(m,2H),2.46–2.40(m,2H),2.01(t,J=2.6Hz,1H),0.15(s,18H),0.13(s,9H),0.11(s,9H)。13C NMR(126MHz,Chloroform-d)δ171.14,93.38,83.12,72.51,70.08,69.54,69.06,61.87,55.71,35.55,14.84。
3g。3.95克(8.44毫摩尔,1.0当量)3b溶于50毫升无水二氯甲烷和吡啶的混合溶剂中(体积比,1/1),反应冰水浴降温到0℃,加入1.0克(8.44毫摩尔,1.0当量)prop-2-yn-1-yl carbonochloridate(4c)。历时2小时反应升温到室温,搅拌过夜,TLC显示反应完全。真空浓缩后得残渣,经硅胶柱纯化得4.59克3g产物。产率99%。α异构体。
化合物3g的核磁检测数据为:1H NMR(500MHz,Chloroform-d)δ5.17(d,J=1.8Hz,1H),4.99(d,J=7.5Hz,1H),4.68(d,J=2.6Hz,2H), 4.05(dd,J=9.1,4.7Hz,1H),3.79(ddd,J=7.0,4.7,1.7Hz,1H),3.69(d,J=3.3Hz,2H),3.64(dt,J=9.3,3.2Hz,1H),3.49(t,J=9.2Hz,1H),2.48(t,J=2.5Hz,1H),0.15(s,9H),0.14(d,J=2.0Hz,18H),0.10(s,9H)。13C NMR(126MHz,Chloroform-d)δ155.51,93.46,78.27,74.68,72.70,70.19,68.94,61.88,57.33,52.58,0.76,0.28,-0.10,-0.27。
3h。16.80克3d(30.49毫摩尔,1.0当量)溶于125毫升二氯甲烷和125毫升的甲醇混合溶剂中,加入4.70克(60.98毫摩尔,2.0当量)乙酸铵。反应在室温搅拌16小时后,真空浓缩,加入100毫升的乙酸乙酯处理,过滤,滤液浓缩后硅胶柱纯化得7.69克3h。产率62%。产物为端基异构体,α/β,1.0/0.3。
化合物3h的核磁检测数据为:1H NMR(500MHz,DMSO-d6)δ7.75(d,J=8.8Hz,1H),7.42(d,J=10.0Hz,0.3H),6.66(d,J=4.5Hz,1H),6.60(d,J=6.9Hz,0.3H),4.85(dd,J=4.5,1.3Hz,1H),4.79(dd,J=6.9,1.3Hz,0.3H),4.42–4.37(m,1.3H),4.20(dd,J=10.0,3.1Hz,0.3H),4.09–4.00(ddd,J=8.8,4.7,1.5Hz,1H),3.94–3.81(m,3.6H),3.69–3.54(m,3.6H),3.54–3.42(m,1.6H),3.18–3.13(m,0.3H)。13C NMR(126MHz,DMSO-d6)δ167.92,167.66,92.90,92.49,76.83,73.29,72.68,70.17,68.63,68.51,60.79,60.71,54.49,54.16,50.90,50.64,40.02,39.86,39.69,39.52,39.35,39.19,39.02,0.81,0.77,0.19,0.16。HRMS(ESI)理论分子量C14H31N4O6Si2[M+H]+407.59400,检测分子量407.59736。
3i。3i以3f为原料合成得到,合成方法参照实施例4中3h的合成。产率为67%。产物为端基异构体,α/β,4/1。
化合物3i的核磁检测数据为:1H NMR(500MHz,Methanol-d4)δ4.96(d,J=1.6Hz,1H),4.27(dd,J=4.6,1.7Hz,1H),4.03(dd,J=8.2,4.6Hz,1H),3.81–3.74(m,4H),3.73–3.69(m,1H),2.54–2.42(m,5H),2.26–2.22(m,1H),0.18–0.14(m,22H)。13C NMR(126MHz,Methanol-d4)δ175.19,95.96,84.61,74.69,72.91,71.31,70.90,62.97,56.60,37.03,16.97,1.93,1.42。
3j。3j以3g为原料合成得到,合成方法参照实施例4中3h的合成, 产率63%。产物为端基异构体,α/β,1.0/0.11。
化合物3j的核磁检测数据为:1H NMR(500MHz,Chloroform-d)δ5.34(s,1H),5.16(d,J=6.4Hz,1H),4.69(d,J=2.5Hz,2H),4.06(dt,J=10.3,5.1Hz,1H),3.92(ddd,J=6.6,4.7,1.7Hz,1H),3.85(ddd,J=9.4,4.8,2.5Hz,1H),3.77(dd,J=11.8,2.6Hz,1H),3.69(dd,J=11.7,5.4Hz,1H),3.58–3.49(m,1H),3.37–3.26(m,1H),2.49(t,J=2.4Hz,1H),0.16(s,9H),0.15(s,9H)。13C NMR(126MHz,Chloroform-d)δ155.72,93.12,77.72,75.33,74.96,70.00,68.80,61.85,55.95,53.42,0.71,0.23。
3k。550毫克(1.35毫摩尔,1.0当量)3h溶于10毫升的吡啶,冰水浴降温到0℃,氮气保护下,加入552毫克(5.41毫摩尔,4.0当量)乙酸酐,反应逐渐升温到室温并反应18小时,加入218微升的甲醇淬灭反应,室温搅拌1小时后,真空浓缩至恒重。残渣用50毫升的甲醇溶解,加入5克的氢离子交换树脂,室温搅拌2小时,TLC显示反应完全。过滤,滤液真空浓缩,残渣用硅胶柱纯化得331毫克的化合物3k。两步产率68%。α/β,1.0/0.28。
化合物3k的核磁检测数据为:1H NMR(500MHz,Methanol-d4,α异构体)δ5.95(d,J=1.8Hz,1H),4.33(dd,J=11.9,2.3Hz,1H),4.29(dd,J=4.8,1.9Hz,1H),4.25(dd,J=12.0,6.5Hz,1H),3.97(dd,J=9.6,4.7Hz,1H),3.95(s,1H),3.94(s,1H),3.81(ddd,J=10.1,6.4,2.4Hz,1H),3.58(t,J=9.7Hz,1H),2.12(s,3H),2.05(s,3H)。13C NMR(151MHz,Methanol-d4,α异构体)δ172.6,170.8,170.1,101.1,93.2,73.7,69.8,68.2,64.6,53.3,52.3,20.50,20.47。1H NMR(500MHz,Methanol-d4,β异构体)δ5.79(d,J=1.8Hz,1H),4.58(dd,J=4.6,1.8Hz,1H),4.42(dd,J=12.0,2.2Hz,1H),4.29(dd,J=11.9,7.0Hz,1H),3.99(s,1H),3.99(s,1H),3.80(dd,J=9.3,4.6Hz,1H),3.61(ddd,J=9.3,7.0,2.3Hz,1H),3.48(t,J=9.5Hz,1H),2.08(s,3H),2.06(s,3H)。13C NMR(126MHz,Methanol-d4,β异构体)δ170.9,169.4,168.5,91.2,75.0,71.0,66.7,63.0,51.4,50.8,18.84,18.77.HRMS(ESI)理论分子量C12H19N4O8[M+H]+347.12029,检测分子量347.11914。
3l。3l按照实施例4中3k的合成路线,以3h和丙酸酐为原料反应得到。两步产率为81%。α异构体。
化合物3l的核磁检测数据为:1H NMR(600MHz,D2O)δ5.96(s,1H),4.47(dd,J=4.7,1.3Hz,1H),4.42(dd,J=12.2,2.0Hz,1H),4.30(dd,J=12.2,6.2Hz,1H),4.15(dd,J=9.8,4.8Hz,1H),4.11(s,2H),3.98–3.94(m,1H),3.70(t,J=9.9Hz,1H),2.51(qd,J=7.5,1.9Hz,2H),2.44(q,J=7.5Hz,2H),1.14(t,J=7.6Hz,3H),1.11(t,J=7.6Hz,3H)。13C NMR(151MHz,D2O)δ177.3,175.2,171.1,92.0,72.1,68.5,66.6,63.3,51.71,51.58,27.21,8.32,8.15.HRMS(ESI)理论分子量C14H23N4O8[M+H]+375.15159,检测分子量375.15095。
3m。3m按照实施例4中3k的合成路线,以3h和丁酸酐为原料反应得到。两步产率为79%。α/β,1.35/1。
3m的核磁检测数据为:α异构体,1H NMR(500MHz,Methanol-d4)δ5.98(d,J=1.8Hz,1H),4.37(dd,J=11.9,2.2Hz,1H),4.29(dd,J=4.9,1.9Hz,1H),4.25(dd,J=11.9,7.0Hz,1H),4.00–3.96(m,2H),3.94(d,J=15.9Hz,1H),3.81(ddd,J=9.5,6.9,2.2Hz,1H),3.57(t,J=9.7Hz,1H),2.39(t,J=7.2Hz,2H),2.31(t,J=7.3Hz,2H),1.68(q,J=7.3Hz,2H),1.63(q,J=7.4Hz,2H),0.99(t,J=7.4Hz,3H),0.94(t,J=7.4Hz,3H)。13C NMR(126MHz,Methanol-d4)δ175.0,172.6,170.7,92.9,73.8,69.9,68.3,64.4,53.3,52.4,36.63,36.59,19.2,19.1,13.72,13.66。β异构体,1H NMR(500MHz,Methanol-d4)δ5.79(d,J=1.8Hz,1H),4.56(dd,J=4.6,1.8Hz,1H),4.39(dd,J=11.9,2.3Hz,1H),4.32(dd,J=12.0,7.1Hz,1H),3.97(s,1H),3.97(s,1H),3.79(dd,J=9.4,4.5Hz,1H),3.59(ddd,J=9.6,7.1,2.4Hz,1H),3.45(t,J=9.4Hz,1H),2.35–2.32(m,2H),2.32–2.28(m,2H),1.63(dh,J=11.7,7.4Hz,4H),0.94(t,J=7.4Hz,6H),0.93(t,J=7.4Hz,3H)。13C NMR(126MHz,Methanol-d4)δ175.0,172.6,171.0,92.7,76.7,72.8,68.6,64.4,53.2,52.5,36.6,36.5,19.2,18.8,13.7,13.6。HRMS(ESI)理论分子量C16H27N4O8[M+H]+403.18289,检测分子量403.18199。
3n。3n以3i为原料经两步合成得到,合成方法参照实施例4中3l的合成。两步总产率为83%。α/β,1.0/0.33。
化合物3n的核磁检测数据为:1H NMR(600MHz,D2O)δ5.94(d,J=1.8Hz,1H,α-H-1),5.86(d,J=1.8Hz,0.33H,β-H-1),4.63(dd,J=4.6,1.8Hz,0.33H,β-H-2),4.44(m,2.33H,β-H-6a+α-H-2+α-H-6a),4.35–4.31(m,0.33H,β-H-6b),4.28(dd,J=12.2,6.3Hz,1H,α-H-6b),4.14(dd,J=9.8,4.9Hz,1H,α-H-3),3.98–3.92(m,1.33H,α-H-5-a+β-H-3),3.81–3.70(m,1.33H,β-H-5+α-H-4),3.63(t,J=9.8Hz,0.33H,β-H-4),2.67–2.35(m,11.97H,COCH2 CH2CCH+2×COCH2 CH3),1.11(m,7.98H,2×COCH2CH3 )。13C NMR(151MHz,D2O)δ177.29(β-COCH2CH3-6),177.26(α-COCH2CH3-6),175.91(β-NHCO),175.44(α-NHCO),175.18(α-COCH2CH3-1),174.95(β-COCH2CH3-1),92.22(α-C-1),91.77(β-C-1),83.58,83.35,74.87(β-C-5),72.04(α-C-5),70.90,70.22,70.11,68.42(α-C-3),66.84(β-C-4),66.67(α-C-4),63.31(α-C-6),63.29(β-C-5),51.77(β-C-2),51.63,34.32,34.08,27.23,27.21,27.19,27.15,14.48,14.43,8.33,8.29,8.16,7.97。
3o。3o以3j为原料经两步合成得到,合成方法参照实施例4中3l的合成,两步总产率为79%。α/β,1.0/0.15。
化合物3o的核磁检测数据为:1H NMR(500MHz,D2O)δ6.02(s,1.0H,α-H-1),5.88(d,J=1.4Hz,0.15H,β-H-1),4.78–4.69(m,2.30H,NHCOOCH2 CCH),4.49(m,1.15H,α-H-6a+β-H-6a),4.37–4.26(m,1.30H,β-H-2+α-H-6b+β-H-6b),4.21(d,J=3.6Hz,1.0H,α-H-2),4.14(dd,J=9.7,4.7Hz,1.0H,α-H-3),3.97(ddd,J=8.7,6.5,2.1Hz,1.15H,α-H-5+β-H-3),3.78(ddd,J=9.2,6.7,2.1Hz,0.15H,β-H-5),3.69(t,J=9.9Hz,1.0H,α-H-4),3.60(t,J=9.8Hz,0.15H,β-H-4),3.10–2.93(m,1.15H,NHCOOCH2CCH),2.57–2.43(m,4.6H,2×CH3CH2 COO),1.20–1.12(m,6.9H,2×CH3 CH2COO)。13C NMR(126MHz,D2O)δ177.40(β-CH3CH2 COO-6),177.38(α-CH3CH2 COO-6),175.25(α-CH3CH2 COO-1),174.98(β-CH3CH2 COO-1),158.33(β-NHCOOCH2CCH),157.61 (α-NHCOOCH2 CCH),92.62(α-C-1),92.04(β-C-1),78.59(β-NHCOOCH2 CCH),78.50(α-NHCOOCH2 CCH),75.93(α-NHCOOCH2CCH),75.87(β-NHCOOCH2CCH),74.92(β-C-5),72.21(α-C-5),71.00(β-C-3),68.73(α-C-3),66.98(β-C-4),66.82(α-C-4),63.53(α-C-6),63.46(β-C-6),54.05(β-C-2),53.43(α-C-2),53.18(NHCOOCH2CCH),27.35(CH3 CH2COO),27.30(CH3 CH2COO),27.26(CH3 CH2COO),8.45(CH3CH2COO),8.41(CH3CH2OCOO),8.30(CH3CH2COO),8.13(CH3CH2COO).
实施例5:1,6-Ac2GalNAz、1,6-Pr2GalNAz、1,6-Bu2GalNAz、6-Ac2GlcNAz、1,6-Pr2GlcNAz、1,6-Bu2GlcNAz,1,6-Ac2ManNAz、1,6-Pr2ManNAz、1,6-Bu2ManNAz与蛋白的体外反应。
为了验证1,6-Ac2GalNAz、1,6-Pr2GalNAz、1,6-Bu2GalNAz、6-Ac2GlcNAz、1,6-Pr2GlcNAz、1,6-Bu2GlcNAz,1,6-Ac2ManNAz、1,6-Pr2ManNAz、1,6-Bu2ManNAz九种部分酰化的非天然糖不能够自发地与蛋白半胱氨酸进行反应,以全乙酰化的非天然糖(Ac4GalNAz,Ac4GlcNAz,Ac4ManNAz)作为对照,将上述部分酰化的非天然糖与HeLa细胞的蛋白裂解液(cell lysates)或单蛋白进行孵育,37℃反应2h后,电泳凝胶检测蛋白上的叠氮信号。反应结果见图1。
实施例6:1,6-Ac2GalNAz、1,6-Pr2GalNAz、1,6-Bu2GalNAz、6-Ac2GlcNAz、1,6-Pr2GlcNAz、1,6-Bu2GlcNAz、1,6-Ac2ManNAz、1,6-Pr2ManNAz、1,6-Bu2ManNAz用于活细胞代谢标记效果。
为了验证上述1,6-双酰化的非天然糖在活细胞中的代谢标记效果,采用上述不同的化合物对HeLa细胞进行代谢标记。具体操作步骤为:
分别将200μM的1,6-双酰化的非天然糖和2mM不带保护基的糖加入HeLa细胞的培养基中进行培养,然后通过与带Cy5荧光标记的物质进行生物正交反应,分别对不同处理后的HeLa细胞进行胶内荧光检测,检测结果见图2(图3中的CBB表示考马斯亮蓝染色,以显示上样量对照)。
从图2可以看出,和GalNAz或者ManNNAz相比,200μM1,6-Pr2GalNAz或1,6-Pr2ManNAz的标记效率接近或者比2mM不带保护基的糖略强。和1,6-Pr2GalNAz或1,6-Pr2ManNAz相比,1,6-Bu2GalNAz或1,6-Bu2ManNAz标记效率相当,但1,6-Ac2GalNAz或者1,6-Ac2ManNAz的标记效率会低很多(图2a和b)。对表达了GFP的MCF-7(MCF7-T2A-GFP)细胞而言,GlcNAz和1,6-双酰化的GlcNAz处理均不会有明显标记(图2c),通过过表达AGX2的突变酶AGX2F383G,该酶能将GlcNAz-P-转变为UDP-GlcNAz,在MCF7-AGX2F383G-T2A-GFP细胞中,GlcNAz和它对应的三种1,6-双酰化衍生物都能产生明显的标记(图2c)。以上数据很好地说明了1,6-双酰化的叠氮糖可以在比不保护的叠氮糖浓度低很多的条件下实现代谢标记。
实施例7:1,6-Pr2ManNAz、1,6-Pr2ManNAl和1,6-Pr2ManNProc用于活细胞代谢标记。
不同的细胞利用200μM的1,6-Pr2ManNAz、1,6-Pr2ManNAl和1,6-Pr2ManNProc代谢标记48小时后,对细胞进行裂解,将带Cy5荧光标记的探针和裂解液中带有正交基团的糖蛋白进行反应,进行生物正交反应,SDS-PAGE分离后,进行胶内荧光分析检测。结果见图3(图3中的CBB表示考马斯亮蓝染色,以显示上样量对照)。
实施例8:1,6-Pr2GalNAz和1,6-Pr2ManNAz用于小鼠活体代谢标记。
小鼠活体试验中,B6D2F1/J小鼠每天腹腔注射1,6-Pr2GalNAz或者1,6-Pr2ManNAz(浓度均为500mg/kg),连续注射3天或者7天。分别在第4天或者第8天对小鼠进行安乐死,选取不同的器官进行匀浆后,对叠氮修饰的糖蛋白进行click标记并进行SDS-PAGE分离。蛋白胶内荧光分析表明,来自心脏、肺和脾脏的糖蛋白都能进行很好地标记,该结果表明1,6-Pr2GalNAz和1,6-Pr2ManNAz能很好地用于活体代谢标记(图4)。
需要特别指出的是,上述各个实施例中的各个组件或步骤均可以相互交叉、替换、增加、删减,因此,这些合理的排列组合变换形成的组合也 应当属于本发明的保护范围,并且不应将本发明的保护范围局限在所述实施例之上。
以上是本发明公开的示例性实施例,上述本发明实施例公开的顺序仅仅为了描述,不代表实施例的优劣。但是应当注意,以上任何实施例的讨论仅为示例性的,并非旨在暗示本发明实施例公开的范围(包括权利要求)被限于这些例子,在不背离权利要求限定的范围的前提下,可以进行多种改变和修改。根据这里描述的公开实施例的方法权利要求的功能、步骤和/或动作不需以任何特定顺序执行。此外,尽管本发明实施例公开的元素可以以个体形式描述或要求,但除非明确限制为单数,也可以理解为多个。
所属领域的普通技术人员应当理解:以上任何实施例的讨论仅为示例性的,并非旨在暗示本发明实施例公开的范围(包括权利要求)被限于这些例子;在本发明实施例的思路下,以上实施例或者不同实施例中的技术特征之间也可以进行组合,并存在如上所述的本发明实施例的不同方面的许多其它变化,为了简明它们没有在细节中提供。因此,凡在本发明实施例的精神和原则之内,所做的任何省略、修改、等同替换、改进等,均应包括在本发明实施例的保护范围之内。

Claims (10)

  1. 一种合成非天然糖的方法,其特征在于,包括:室温下,将氨基糖的羟基进行全三甲基硅烷保护,选择性地暴露糖上的氨基,将所述氨基在室温下进行偶联、转化后,得到全三甲基硅烷保护的带有正交基团的非天然糖。
  2. 根据权利要求1所述的方法,其特征在于,将所述全三甲基硅烷保护的带有正交基团的非天然糖脱除三甲基硅烷保护基,得到不带保护基的非天然糖。
  3. 根据权利要求2所述的方法,其特征在于,所述不带保护基的非天然糖为GalNAz、GlcNAz、ManNAz、GalNAl、GlcNAl和ManNAl中的任意一种;
    其中,GalNAz、GlcNAz、ManNAz的合成过程中,脱除三甲基硅烷保护基采用氢离子交换树脂脱除,终产物从溶剂中沉淀析出;
    ManNAl的合成过程中,脱除三甲基硅烷保护基采用硅胶柱色谱纯化。
  4. 根据权利要求1所述的方法,其特征在于,所述全三甲基硅烷三甲基硅烷保护的带有正交基团的非天然糖的1号位和6号位的羟基被疏水基团保护,得到部分酰化的非天然糖。
  5. 根据权利要求4所述的方法,其特征在于,所述疏水基团为乙酰基、丙酰基、丁酰基和戊酰基中的任意一种。
  6. 根据权利要求4所述的方法,其特征在于,对于半乳糖型和葡萄糖型的全三甲基硅烷三甲基硅烷保护的带有正交基团的非天然糖,以吡啶为溶剂,加入四个当量的羧酸和大过量的对应酸酐,全三甲基硅烷保护的非天然糖的1号位和6号位的三甲基硅烷保护基被交换成对应的酯键,利用氢离子交换树脂脱除3号位和4号位的三甲基硅烷保护基后,得到1,6-双酰化非天然糖;
    对于甘露糖型的全三甲基硅烷保护的带有正交基团的非天然糖,在二氯甲烷和甲醇的混合溶剂中,加入两个当量的醋酸铵选择性地同时脱除1号位和6号位的三甲基硅烷保护基,在吡啶中对1号位和6号位进行酯键保护,随后脱除糖的3号位和4号位的三甲基硅烷保护基,得到1,6-双酰化的甘露 糖型非天然糖衍生物。
  7. 根据权利要求1所述的方法,其特征在于,所述全三甲基硅烷保护的带有正交基团的非天然糖的正交基团为叠氮、端炔、端烯、环丙烯、反式环辛烯、环辛炔中的任意一种。
  8. 一种用于代谢标记的部分酰化的非天然糖,其特征在于,为1,6-Ac2GalNAz、1,6-Pr2GalNAz、1,6-Bu2GalNAz、1,6-Ac2GlcNAz、1,6-Pr2GlcNAz、1,6-Bu2GlcNAz、1,6-Ac2ManNAz、1,6-Pr2ManNAz、1,6-Bu2ManNAz、1,6-Pr2ManNAl和1,6-Pr2ManNProc中的任意一种;
    优选地,所述用于代谢标记的部分酰化的非天然糖采用权利要求1-7任意一项所述的方法制成。
  9. 一种糖代谢标记试剂盒,其特征在于,包括权利要求8所述的部分酰化的非天然糖。
  10. 根据权利要求8所述的一种部分酰化的非天然糖在糖代谢标记试剂盒中的应用,对HeLa细胞、3T3细胞、CHO细胞和MCF-7细胞中的任意一种细胞的糖代谢标记。
PCT/CN2023/112917 2022-10-27 2023-08-14 非天然糖及其合成方法和应用 WO2024087806A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202211329008.3 2022-10-27
CN202211329008.3A CN115677798A (zh) 2022-10-27 2022-10-27 非天然糖及其合成方法和应用

Publications (1)

Publication Number Publication Date
WO2024087806A1 true WO2024087806A1 (zh) 2024-05-02

Family

ID=85098479

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/112917 WO2024087806A1 (zh) 2022-10-27 2023-08-14 非天然糖及其合成方法和应用

Country Status (2)

Country Link
CN (1) CN115677798A (zh)
WO (1) WO2024087806A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115677798A (zh) * 2022-10-27 2023-02-03 北京大学 非天然糖及其合成方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102993256A (zh) * 2012-12-31 2013-03-27 浙江大学 一种选择性脱除全三甲基硅基保护糖的伯位三甲基硅基的方法
CN104177451A (zh) * 2013-05-23 2014-12-03 北京大学 非天然双功能糖及其制备方法和应用
CN115677798A (zh) * 2022-10-27 2023-02-03 北京大学 非天然糖及其合成方法和应用
CN116217638A (zh) * 2023-05-10 2023-06-06 南京大学 硒代非天然糖及其制备方法和应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102993256A (zh) * 2012-12-31 2013-03-27 浙江大学 一种选择性脱除全三甲基硅基保护糖的伯位三甲基硅基的方法
CN104177451A (zh) * 2013-05-23 2014-12-03 北京大学 非天然双功能糖及其制备方法和应用
CN115677798A (zh) * 2022-10-27 2023-02-03 北京大学 非天然糖及其合成方法和应用
CN116217638A (zh) * 2023-05-10 2023-06-06 南京大学 硒代非天然糖及其制备方法和应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BO CHENG: "Facile Synthesis of Clickable Unnatural Sugars in the Unprotected and 1,6‐Di‐ O ‐Acylated Forms for Metabolic Glycan Labeling", CHEMISTRY - A EUROPEAN JOURNAL, JOHN WILEY & SONS, INC, DE, vol. 29, no. 11, 21 February 2023 (2023-02-21), DE, XP093162767, ISSN: 0947-6539, DOI: 10.1002/chem.202203054 *
KE QIN: "Protein S-Glyco-Modification through an Elimination–Addition Mechanism", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, AMERICAN CHEMICAL SOCIETY, vol. 142, no. 20, 20 May 2020 (2020-05-20), pages 9382 - 9388, XP093162770, ISSN: 0002-7863, DOI: 10.1021/jacs.0c02110 *
WELDAY DESTA WELDU: "Selective Acetylation of Non-anomeric Groups of per- O -Trimethylsilylated Sugars", THE JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY, vol. 86, no. 7, 2 April 2021 (2021-04-02), pages 5336 - 5344, XP093162773, ISSN: 0022-3263, DOI: 10.1021/acs.joc.0c02813 *

Also Published As

Publication number Publication date
CN115677798A (zh) 2023-02-03

Similar Documents

Publication Publication Date Title
WO2024087806A1 (zh) 非天然糖及其合成方法和应用
US5220043A (en) Synthesis of D-erythro-sphingomyelins
SU902666A3 (ru) Способ получени плевромутилиновых гликозидных производных
KR100559817B1 (ko) 스핑고신 유사화합물
DE3874352T2 (de) Lipophile salze von s-adenosyl-l-methionin (sam) mit acyltaurinderivaten.
Kiso et al. Synthesis of 2-deoxy-4-O-phosphono-3-O-tetradecanoyl-2-[(3R-and (3S)-3-tetradecanoyloxytetradecanamido]-d-glucose: a diastereoisomeric pair of 4-O-phosphono-d-glucosamine derivatives (GLA-27) related to bacterial lipid A
JPH0826057B2 (ja) シアル酸オリゴ糖誘導体及び微粒子キャリヤー
DE60027905T2 (de) Glycokonjugate, glycoaminosäure, deren zwischenprodukte, und ihre verwendung
Polyakova et al. New GM1 ganglioside derivatives for selective single and double labelling of the natural glycosphingolipid skeleton
EP0060999B1 (de) Galactopyranoside Verbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung als Antigene oder Immunadsorbentien
Marchesini et al. Synthesis, spectral properties and enzymatic hydrolysis of fluorescent derivatives of cerebroside sulfate containing long-wavelength-emission probes
CN111208284B (zh) 糖代谢标记探针、包含其的试剂盒及其应用
EP0271552A1 (en) Derivatives of (trans) -retinoic acid and (cis) -13-retinoic acid and methods of preparation
EP0188647B1 (en) Acylated derivatives of cytidine-diphosphate-choline, process for their preparation and their therapeutic use
EP0315973A2 (en) Sialocylglycerolipids and method for preparing the same
Bellosta et al. Synthesis of (2-deoxy-α-d-glyc-2-enopyranosyl) arenes by stereospecific counjugate-addition of organocopper reagents to peracetylated hex-1-enopyran-3-uloses
AU2020103289A4 (en) Preparation and Application of Alkaloid Derivatives for Reversing Human Tumor Drug Resistance and Anti-canine Breast Cancer
Flowers Substituted cerebrosides: Part II. Synthetic dihydrosulfatides
WO2022017317A1 (zh) 一种规模化合成河豚毒素的方法
US5712377A (en) Glycosides isolated from pollen, their sugar-free decomposition products and derivatives thereof
JPH0569117B2 (zh)
US6423702B1 (en) Process for the hydroxylation of an acyclic or cyclic methylene radical in the allylic position, pharmaceutical composition containing hydroxycholesterol derivatives and utilization of such compositions for the preparation of drugs
CA1247608A (fr) Derives a structure acide uronique, leur preparation et leurs applications biologiques
CN117417395A (zh) 非天然磷酸糖及其制备方法、糖代谢标记试剂盒和它们的应用
DD217210A1 (de) Verfahren zur herstellung von l-alanyl-d-isoglutaminyl-adamantylamid

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23881390

Country of ref document: EP

Kind code of ref document: A1